HITId,original_text,key_strokes,datetime,text,copied,predicted
309D674SHZ6NLN8CVPB7DNTRX7EBCC,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",Backspace Backspace Backspace Backspace Backspace Backspace Shift w E Backspace Backspace Backspace Backspace Backspace Backspace CapsLock Shift W e r a n d o m l u Backspace y a s s i g n e d 8 1 1 Control c copy Control v paste Control c copy Control v paste Backspace Shift P .,"['2023-06-01T07:06:03.732Z', '2023-06-01T07:06:03.891Z', '2023-06-01T07:06:04.043Z', '2023-06-01T07:06:45.955Z', '2023-06-01T07:06:46.106Z', '2023-06-01T07:06:46.250Z', '2023-06-01T07:06:55.675Z', '2023-06-01T07:06:55.858Z', '2023-06-01T07:06:56.154Z', '2023-06-01T07:06:56.586Z', '2023-06-01T07:06:57.258Z', '2023-06-01T07:06:57.418Z', '2023-06-01T07:06:58.258Z', '2023-06-01T07:06:58.418Z', '2023-06-01T07:06:58.570Z', '2023-06-01T07:06:58.714Z', '2023-06-01T07:06:58.890Z', '2023-06-01T07:06:59.243Z', '2023-06-01T07:06:59.497Z', '2023-06-01T07:06:59.802Z', '2023-06-01T07:07:00.018Z', '2023-06-01T07:07:13.338Z', '2023-06-01T07:07:13.626Z', '2023-06-01T07:07:13.850Z', '2023-06-01T07:07:14.409Z', '2023-06-01T07:07:14.649Z', '2023-06-01T07:07:15.929Z', '2023-06-01T07:07:24.378Z', '2023-06-01T07:07:24.641Z', '2023-06-01T07:07:25.529Z', '2023-06-01T07:07:26.041Z', '2023-06-01T07:07:26.297Z', '2023-06-01T07:07:26.905Z', '2023-06-01T07:07:27.217Z', '2023-06-01T07:07:27.433Z', '2023-06-01T07:07:27.633Z', '2023-06-01T07:07:28.225Z', '2023-06-01T07:07:28.417Z', '2023-06-01T07:07:28.561Z', '2023-06-01T07:07:28.801Z', '2023-06-01T07:07:28.977Z', '2023-06-01T07:07:31.265Z', '2023-06-01T07:07:31.553Z', '2023-06-01T07:07:31.721Z', '2023-06-01T07:07:32.353Z', '2023-06-01T07:07:44.393Z', '2023-06-01T07:07:44.553Z', None, '2023-06-01T07:07:45.858Z', '2023-06-01T07:07:46.057Z', None, '2023-06-01T07:12:11.676Z', '2023-06-01T07:12:11.868Z', None, '2023-06-01T07:12:13.220Z', '2023-06-01T07:12:13.372Z', None, '2023-06-01T07:12:16.339Z', '2023-06-01T07:12:16.796Z', '2023-06-01T07:12:16.987Z', '2023-06-01T07:12:20.091Z']","We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%.Participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein.",True,real
309D674SHZ6NLN8CVPB7DNTRX7EBCC,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",copy paste copy paste,"[None, None, None, None]","onths, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons).We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. ",True,real
309D674SHZ6NLN8CVPB7DNTRX7EBCC,"Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates

The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year.

We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content.

At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P) 0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels.
",copy paste,"[None, None]","In this two-year study of 811 overweight adults, diets with low to moderate fat (20 to 40%), high to moderate protein (15 to 25%), and low to high carbohydrates (35 to 65%) all resulted in similar average weight loss of 3-4 kg after two years. Participants attending more sessions had a greater average weight loss, although their diets also improved their metabolic health indiicators. In conclusion, the composition of fat, protein, and carbs in a diet did not seem to strongly influence weight loss.",True,real
3XABXM4AJ1Q8DQKOXVSS6QS7TGU8QF,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
","Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift Shift T h e n o r w e g i a n b r e a s t - Backspace Shift N c a n c e r s c r e e n i n g p r o g r a m w a s s t a r t e d i n 1 9 9 6 . Shift W o m e n b e t w e e n t h e a g e s 5 0 a n d 6 9 y e a r s w e r e o f f e r e d s c r e e n i n g m a m m o g r a p h y e v e r y 2 y e a r s . w e c o m p a r e d t h e i n c i d e n c e Backspace b a s e d r a t e s o f d e a t h f r o m b r e a s t c a n c e r i n f o u r g r o u p s Shift : t w o g r o u p s o f w o m e n - w h o f r o m 1 9 9 6 t h r o u g h 2 0 0 5 l i v i n g i n c o u n t i e s w i t h s c r e e n i n g o r w i t h o u t s c r e e n i n g a n d t w o h i s t o r i c a l - c o m p a r i s o n g r o u p s t h a t f r o m 1 9 8 6 t h r o u g h 1 9 5 5 Backspace Backspace 9 5 . Enter w Backspace Shift W e a n a l y z e d d a t a f r o m 4 0 , 0 7 5 w o m e n w i t h b r e a s t c a n c e r . Shift T h e r a t e o f d e a t h w a s r e d u c e d b y 7 . 2 d e a t h s p e r 1 0 0 , 0 0 p e r s o n - y e a r s i n t h e s c r e e n i n g g r o u p c o m p a r e d w i t h h i s t o r i c a l s c r e e n i n g g r o u p a n d b y 4 . 8 d e a t h s p e r 1 0 0 , 0 0 0 p e r s o n - y e a r s i n n o n Backspace s c r e e n i n g g r o u p s Backspace a s Backspace Backspace a s c o m p a r e d w i t h h i s t o r i c a l n o n s c r e e n i n g g r o u p . Enter Shift T h e a v a i l a b i l i t y o f s c r e e n i n g m a m m o g r a p h y w a s a s s o c i a t e d w i t h a r e d u c t i o n i n t h e r a t e o f d e a t h f r o m b r e a s t c a n c e r .","['2023-06-01T10:42:22.995Z', '2023-06-01T10:42:23.444Z', '2023-06-01T10:42:23.472Z', '2023-06-01T10:42:23.504Z', '2023-06-01T10:42:23.536Z', '2023-06-01T10:42:23.568Z', '2023-06-01T10:42:23.601Z', '2023-06-01T10:42:23.636Z', '2023-06-01T10:42:23.675Z', '2023-06-01T10:42:23.711Z', '2023-06-01T10:42:23.740Z', '2023-06-01T10:42:23.787Z', '2023-06-01T10:42:23.803Z', '2023-06-01T10:42:23.841Z', '2023-06-01T10:42:23.875Z', '2023-06-01T10:42:23.905Z', '2023-06-01T10:42:23.938Z', '2023-06-01T10:42:23.974Z', '2023-06-01T10:42:24.005Z', '2023-06-01T10:42:24.054Z', '2023-06-01T10:42:24.066Z', '2023-06-01T10:42:24.109Z', '2023-06-01T10:42:24.134Z', '2023-06-01T10:42:24.170Z', '2023-06-01T10:42:24.196Z', '2023-06-01T10:42:24.229Z', '2023-06-01T10:42:24.260Z', '2023-06-01T10:42:24.305Z', '2023-06-01T10:42:24.337Z', '2023-06-01T10:42:24.373Z', '2023-06-01T10:42:24.400Z', '2023-06-01T10:42:24.427Z', '2023-06-01T10:42:24.470Z', '2023-06-01T10:42:24.495Z', '2023-06-01T10:42:24.530Z', '2023-06-01T10:42:24.564Z', '2023-06-01T10:42:24.600Z', '2023-06-01T10:42:24.626Z', '2023-06-01T10:42:24.658Z', '2023-06-01T10:42:24.690Z', '2023-06-01T10:42:24.727Z', '2023-06-01T10:42:24.755Z', '2023-06-01T10:42:24.794Z', '2023-06-01T10:42:24.824Z', '2023-06-01T10:42:24.867Z', '2023-06-01T10:42:24.887Z', '2023-06-01T10:42:24.921Z', '2023-06-01T10:42:24.974Z', '2023-06-01T10:42:24.987Z', '2023-06-01T10:42:25.023Z', '2023-06-01T10:42:25.111Z', '2023-06-01T10:42:25.117Z', '2023-06-01T10:42:25.120Z', '2023-06-01T10:42:25.160Z', '2023-06-01T10:42:25.190Z', '2023-06-01T10:42:25.219Z', '2023-06-01T10:42:25.256Z', '2023-06-01T10:42:25.288Z', '2023-06-01T10:42:25.320Z', '2023-06-01T10:42:25.356Z', '2023-06-01T10:42:25.391Z', '2023-06-01T10:42:25.421Z', '2023-06-01T10:42:25.449Z', '2023-06-01T10:42:25.491Z', '2023-06-01T10:42:25.515Z', '2023-06-01T10:42:25.562Z', '2023-06-01T10:42:25.591Z', '2023-06-01T10:42:25.620Z', '2023-06-01T10:42:25.659Z', '2023-06-01T10:42:25.691Z', '2023-06-01T10:42:25.723Z', '2023-06-01T10:42:25.757Z', '2023-06-01T10:42:25.788Z', '2023-06-01T10:42:25.825Z', '2023-06-01T10:42:25.856Z', '2023-06-01T10:42:25.894Z', '2023-06-01T10:42:25.924Z', '2023-06-01T10:42:25.956Z', '2023-06-01T10:42:25.979Z', '2023-06-01T10:42:26.014Z', '2023-06-01T10:42:26.057Z', '2023-06-01T10:42:26.082Z', '2023-06-01T10:42:26.116Z', '2023-06-01T10:42:26.158Z', '2023-06-01T10:42:26.181Z', '2023-06-01T10:42:26.209Z', '2023-06-01T10:42:26.256Z', '2023-06-01T10:42:26.276Z', '2023-06-01T10:42:26.314Z', '2023-06-01T10:42:26.346Z', '2023-06-01T10:42:26.378Z', '2023-06-01T10:42:26.407Z', '2023-06-01T10:42:26.443Z', '2023-06-01T10:42:26.479Z', '2023-06-01T10:42:26.507Z', '2023-06-01T10:42:26.537Z', '2023-06-01T10:42:26.572Z', '2023-06-01T10:42:26.608Z', '2023-06-01T10:42:26.642Z', '2023-06-01T10:42:26.677Z', '2023-06-01T10:42:28.366Z', '2023-06-01T10:42:28.873Z', '2023-06-01T10:42:28.897Z', '2023-06-01T10:42:29.739Z', '2023-06-01T10:42:29.960Z', '2023-06-01T10:42:30.162Z', '2023-06-01T10:42:30.417Z', '2023-06-01T10:42:30.631Z', '2023-06-01T10:42:30.870Z', '2023-06-01T10:42:31.414Z', '2023-06-01T10:42:31.598Z', '2023-06-01T10:42:32.029Z', '2023-06-01T10:42:32.256Z', '2023-06-01T10:42:32.379Z', '2023-06-01T10:42:32.656Z', '2023-06-01T10:42:33.174Z', '2023-06-01T10:42:33.481Z', '2023-06-01T10:42:33.841Z', '2023-06-01T10:42:33.959Z', '2023-06-01T10:42:34.159Z', '2023-06-01T10:42:34.337Z', '2023-06-01T10:42:34.571Z', '2023-06-01T10:42:35.856Z', '2023-06-01T10:42:39.928Z', '2023-06-01T10:42:40.585Z', '2023-06-01T10:42:40.873Z', '2023-06-01T10:42:44.351Z', '2023-06-01T10:42:44.575Z', '2023-06-01T10:42:44.713Z', '2023-06-01T10:42:44.895Z', '2023-06-01T10:42:45.190Z', '2023-06-01T10:42:45.321Z', '2023-06-01T10:42:45.577Z', '2023-06-01T10:42:45.802Z', '2023-06-01T10:42:46.081Z', '2023-06-01T10:42:46.343Z', '2023-06-01T10:42:46.553Z', '2023-06-01T10:42:46.721Z', '2023-06-01T10:42:47.132Z', '2023-06-01T10:42:47.305Z', '2023-06-01T10:42:47.511Z', '2023-06-01T10:42:47.738Z', '2023-06-01T10:42:47.897Z', '2023-06-01T10:42:48.086Z', '2023-06-01T10:42:48.231Z', '2023-06-01T10:42:48.368Z', '2023-06-01T10:42:48.769Z', '2023-06-01T10:42:49.060Z', '2023-06-01T10:42:49.232Z', '2023-06-01T10:42:49.456Z', '2023-06-01T10:42:49.706Z', '2023-06-01T10:42:49.861Z', '2023-06-01T10:42:49.978Z', '2023-06-01T10:42:50.162Z', '2023-06-01T10:42:50.367Z', '2023-06-01T10:42:50.511Z', '2023-06-01T10:42:50.719Z', '2023-06-01T10:42:51.123Z', '2023-06-01T10:42:51.505Z', '2023-06-01T10:42:51.738Z', '2023-06-01T10:42:51.959Z', '2023-06-01T10:42:52.187Z', '2023-06-01T10:42:52.427Z', '2023-06-01T10:42:52.627Z', '2023-06-01T10:42:52.897Z', '2023-06-01T10:42:53.099Z', '2023-06-01T10:42:54.426Z', '2023-06-01T10:42:54.905Z', '2023-06-01T10:42:55.087Z', '2023-06-01T10:42:55.627Z', '2023-06-01T10:42:59.431Z', '2023-06-01T10:43:00.279Z', '2023-06-01T10:43:00.913Z', '2023-06-01T10:43:01.397Z', '2023-06-01T10:43:01.562Z', '2023-06-01T10:43:02.096Z', '2023-06-01T10:43:03.000Z', '2023-06-01T10:43:03.203Z', '2023-06-01T10:43:03.379Z', '2023-06-01T10:43:03.601Z', '2023-06-01T10:43:03.794Z', '2023-06-01T10:43:03.986Z', '2023-06-01T10:43:04.223Z', '2023-06-01T10:43:04.448Z', '2023-06-01T10:43:04.812Z', '2023-06-01T10:43:04.976Z', '2023-06-01T10:43:05.354Z', '2023-06-01T10:43:05.617Z', '2023-06-01T10:43:05.947Z', '2023-06-01T10:43:06.129Z', '2023-06-01T10:43:06.252Z', '2023-06-01T10:43:06.394Z', '2023-06-01T10:43:06.490Z', '2023-06-01T10:43:06.722Z', '2023-06-01T10:43:06.940Z', '2023-06-01T10:43:07.190Z', '2023-06-01T10:43:07.337Z', '2023-06-01T10:43:08.227Z', '2023-06-01T10:43:08.498Z', '2023-06-01T10:43:09.385Z', '2023-06-01T10:43:09.533Z', '2023-06-01T10:43:09.665Z', '2023-06-01T10:43:09.834Z', '2023-06-01T10:43:09.924Z', '2023-06-01T10:43:11.369Z', '2023-06-01T10:43:11.648Z', '2023-06-01T10:43:12.649Z', '2023-06-01T10:43:13.019Z', '2023-06-01T10:43:13.119Z', '2023-06-01T10:43:13.320Z', '2023-06-01T10:43:13.545Z', '2023-06-01T10:43:13.776Z', '2023-06-01T10:43:13.972Z', '2023-06-01T10:43:14.101Z', '2023-06-01T10:43:14.176Z', '2023-06-01T10:43:14.300Z', '2023-06-01T10:43:14.483Z', '2023-06-01T10:43:15.116Z', '2023-06-01T10:43:15.337Z', '2023-06-01T10:43:15.463Z', '2023-06-01T10:43:15.645Z', '2023-06-01T10:43:15.848Z', '2023-06-01T10:43:15.944Z', '2023-06-01T10:43:16.249Z', '2023-06-01T10:43:16.493Z', '2023-06-01T10:43:16.680Z', '2023-06-01T10:43:16.802Z', '2023-06-01T10:43:17.048Z', '2023-06-01T10:43:17.275Z', '2023-06-01T10:43:17.535Z', '2023-06-01T10:43:17.712Z', '2023-06-01T10:43:18.025Z', '2023-06-01T10:43:18.249Z', '2023-06-01T10:43:18.424Z', '2023-06-01T10:43:18.664Z', '2023-06-01T10:43:21.331Z', '2023-06-01T10:43:21.623Z', '2023-06-01T10:43:21.817Z', '2023-06-01T10:43:22.119Z', '2023-06-01T10:43:22.361Z', '2023-06-01T10:43:22.700Z', '2023-06-01T10:43:22.872Z', '2023-06-01T10:43:23.136Z', '2023-06-01T10:43:23.403Z', '2023-06-01T10:43:23.738Z', '2023-06-01T10:43:23.979Z', '2023-06-01T10:43:24.225Z', '2023-06-01T10:43:24.417Z', '2023-06-01T10:43:24.566Z', '2023-06-01T10:43:24.865Z', '2023-06-01T10:43:25.128Z', '2023-06-01T10:43:25.269Z', '2023-06-01T10:43:25.548Z', '2023-06-01T10:43:25.833Z', '2023-06-01T10:43:26.939Z', '2023-06-01T10:43:27.853Z', '2023-06-01T10:43:28.136Z', '2023-06-01T10:43:28.260Z', '2023-06-01T10:43:28.485Z', '2023-06-01T10:43:28.712Z', '2023-06-01T10:43:29.072Z', '2023-06-01T10:43:29.732Z', '2023-06-01T10:44:14.125Z', '2023-06-01T10:44:14.312Z', '2023-06-01T10:44:14.499Z', '2023-06-01T10:44:14.704Z', '2023-06-01T10:44:14.856Z', '2023-06-01T10:44:15.031Z', '2023-06-01T10:44:15.233Z', '2023-06-01T10:44:15.985Z', '2023-06-01T10:44:16.148Z', '2023-06-01T10:44:16.383Z', '2023-06-01T10:44:16.650Z', '2023-06-01T10:44:16.902Z', '2023-06-01T10:44:17.418Z', '2023-06-01T10:44:17.564Z', '2023-06-01T10:44:17.779Z', '2023-06-01T10:44:17.893Z', '2023-06-01T10:44:18.017Z', '2023-06-01T10:44:18.153Z', '2023-06-01T10:44:18.312Z', '2023-06-01T10:44:18.440Z', '2023-06-01T10:44:18.625Z', '2023-06-01T10:44:18.738Z', '2023-06-01T10:44:18.951Z', '2023-06-01T10:44:19.623Z', '2023-06-01T10:44:19.808Z', '2023-06-01T10:44:20.082Z', '2023-06-01T10:44:20.276Z', '2023-06-01T10:44:20.899Z', '2023-06-01T10:44:21.649Z', '2023-06-01T10:44:21.874Z', '2023-06-01T10:44:22.002Z', '2023-06-01T10:44:22.282Z', '2023-06-01T10:44:22.522Z', '2023-06-01T10:44:22.681Z', '2023-06-01T10:44:22.814Z', '2023-06-01T10:44:22.988Z', '2023-06-01T10:44:23.187Z', '2023-06-01T10:44:23.386Z', '2023-06-01T10:44:23.611Z', '2023-06-01T10:44:23.770Z', '2023-06-01T10:44:23.962Z', '2023-06-01T10:44:24.108Z', '2023-06-01T10:44:24.432Z', '2023-06-01T10:44:24.787Z', '2023-06-01T10:44:24.993Z', '2023-06-01T10:44:25.157Z', '2023-06-01T10:44:25.370Z', '2023-06-01T10:44:25.611Z', '2023-06-01T10:44:25.998Z', '2023-06-01T10:44:26.276Z', '2023-06-01T10:44:26.489Z', '2023-06-01T10:44:26.689Z', '2023-06-01T10:44:26.931Z', '2023-06-01T10:44:27.115Z', '2023-06-01T10:44:27.305Z', '2023-06-01T10:44:27.424Z', '2023-06-01T10:44:27.564Z', '2023-06-01T10:44:27.741Z', '2023-06-01T10:44:27.938Z', '2023-06-01T10:44:28.156Z', '2023-06-01T10:44:28.329Z', '2023-06-01T10:44:28.485Z', '2023-06-01T10:44:28.636Z', '2023-06-01T10:44:28.796Z', '2023-06-01T10:44:28.930Z', '2023-06-01T10:44:29.178Z', '2023-06-01T10:44:29.336Z', '2023-06-01T10:44:29.618Z', '2023-06-01T10:44:29.904Z', '2023-06-01T10:44:30.113Z', '2023-06-01T10:44:30.281Z', '2023-06-01T10:44:31.370Z', '2023-06-01T10:44:31.600Z', '2023-06-01T10:44:32.282Z', '2023-06-01T10:44:32.432Z', '2023-06-01T10:44:32.688Z', '2023-06-01T10:44:32.862Z', '2023-06-01T10:44:33.117Z', '2023-06-01T10:44:33.297Z', '2023-06-01T10:44:33.506Z', '2023-06-01T10:44:33.747Z', '2023-06-01T10:45:01.871Z', '2023-06-01T10:45:02.250Z', '2023-06-01T10:45:02.600Z', '2023-06-01T10:45:02.954Z', '2023-06-01T10:45:03.191Z', '2023-06-01T10:45:03.427Z', '2023-06-01T10:45:03.645Z', '2023-06-01T10:45:03.804Z', '2023-06-01T10:45:03.913Z', '2023-06-01T10:45:04.153Z', '2023-06-01T10:45:04.280Z', '2023-06-01T10:45:04.488Z', '2023-06-01T10:45:04.697Z', '2023-06-01T10:45:04.843Z', '2023-06-01T10:45:04.993Z', '2023-06-01T10:45:05.193Z', '2023-06-01T10:45:05.321Z', '2023-06-01T10:45:05.444Z', '2023-06-01T10:45:05.624Z', '2023-06-01T10:45:05.759Z', '2023-06-01T10:45:06.021Z', '2023-06-01T10:45:06.713Z', '2023-06-01T10:45:07.102Z', '2023-06-01T10:45:12.979Z', '2023-06-01T10:45:18.385Z', '2023-06-01T10:45:18.643Z', '2023-06-01T10:45:18.816Z', '2023-06-01T10:45:18.977Z', '2023-06-01T10:45:19.185Z', '2023-06-01T10:45:19.329Z', '2023-06-01T10:45:19.570Z', '2023-06-01T10:45:19.665Z', '2023-06-01T10:45:19.888Z', '2023-06-01T10:45:20.035Z', '2023-06-01T10:45:20.858Z', '2023-06-01T10:45:21.158Z', '2023-06-01T10:45:21.336Z', '2023-06-01T10:45:21.552Z', '2023-06-01T10:45:22.547Z', '2023-06-01T10:45:22.773Z', '2023-06-01T10:45:22.961Z', '2023-06-01T10:45:23.112Z', '2023-06-01T10:45:23.218Z', '2023-06-01T10:45:23.373Z', '2023-06-01T10:45:23.569Z', '2023-06-01T10:45:23.717Z', '2023-06-01T10:45:23.936Z', '2023-06-01T10:45:24.880Z', '2023-06-01T10:45:25.109Z', '2023-06-01T10:45:25.280Z', '2023-06-01T10:45:25.586Z', '2023-06-01T10:45:26.568Z', '2023-06-01T10:45:26.763Z', '2023-06-01T10:45:26.969Z', '2023-06-01T10:45:27.146Z', '2023-06-01T10:45:27.272Z', '2023-06-01T10:45:27.490Z', '2023-06-01T10:45:28.060Z', '2023-06-01T10:45:28.225Z', '2023-06-01T10:45:28.417Z', '2023-06-01T10:45:28.648Z', '2023-06-01T10:45:28.785Z', '2023-06-01T10:45:28.954Z', '2023-06-01T10:45:29.066Z', '2023-06-01T10:45:29.233Z', '2023-06-01T10:45:29.481Z', '2023-06-01T10:45:29.705Z', '2023-06-01T10:45:29.882Z', '2023-06-01T10:45:30.020Z', '2023-06-01T10:45:30.591Z', '2023-06-01T10:45:30.872Z', '2023-06-01T10:45:31.244Z', '2023-06-01T10:45:31.450Z', '2023-06-01T10:45:31.599Z', '2023-06-01T10:45:31.770Z', '2023-06-01T10:45:31.952Z', '2023-06-01T10:45:32.125Z', '2023-06-01T10:45:32.328Z', '2023-06-01T10:45:32.610Z', '2023-06-01T10:45:32.850Z', '2023-06-01T10:45:33.008Z', '2023-06-01T10:45:33.235Z', '2023-06-01T10:45:33.440Z', '2023-06-01T10:45:33.608Z', '2023-06-01T10:45:33.880Z', '2023-06-01T10:45:34.025Z', '2023-06-01T10:45:34.209Z', '2023-06-01T10:45:34.380Z', '2023-06-01T10:45:34.522Z', '2023-06-01T10:45:34.706Z', '2023-06-01T10:45:34.886Z', '2023-06-01T10:45:35.044Z', '2023-06-01T10:45:35.303Z', '2023-06-01T10:45:35.616Z', '2023-06-01T10:45:35.839Z', '2023-06-01T10:45:36.050Z', '2023-06-01T10:45:36.339Z', '2023-06-01T10:45:36.515Z', '2023-06-01T10:45:36.774Z', '2023-06-01T10:45:37.090Z', '2023-06-01T10:45:37.250Z', '2023-06-01T10:45:37.428Z', '2023-06-01T10:45:37.737Z', '2023-06-01T10:45:37.959Z', '2023-06-01T10:45:38.135Z', '2023-06-01T10:45:38.443Z', '2023-06-01T10:45:38.792Z', '2023-06-01T10:45:39.474Z', '2023-06-01T10:45:39.620Z', '2023-06-01T10:45:39.783Z', '2023-06-01T10:45:39.929Z', '2023-06-01T10:45:40.094Z', '2023-06-01T10:45:40.307Z', '2023-06-01T10:45:40.523Z', '2023-06-01T10:45:40.780Z', '2023-06-01T10:45:40.985Z', '2023-06-01T10:45:41.130Z', '2023-06-01T10:45:41.288Z', '2023-06-01T10:45:41.466Z', '2023-06-01T10:45:41.562Z', '2023-06-01T10:45:41.721Z', '2023-06-01T10:45:41.880Z', '2023-06-01T10:45:42.099Z', '2023-06-01T10:45:42.248Z', '2023-06-01T10:45:42.481Z', '2023-06-01T10:45:44.057Z', '2023-06-01T10:45:44.697Z', '2023-06-01T10:45:45.097Z', '2023-06-01T10:45:45.288Z', '2023-06-01T10:45:46.065Z', '2023-06-01T10:45:46.265Z', '2023-06-01T10:45:46.505Z', '2023-06-01T10:45:46.770Z', '2023-06-01T10:45:47.029Z', '2023-06-01T10:45:47.219Z', '2023-06-01T10:45:47.473Z', '2023-06-01T10:45:47.763Z', '2023-06-01T10:45:47.907Z', '2023-06-01T10:45:48.154Z', '2023-06-01T10:45:48.299Z', '2023-06-01T10:45:48.489Z', '2023-06-01T10:45:48.681Z', '2023-06-01T10:45:48.872Z', '2023-06-01T10:45:49.104Z', '2023-06-01T10:45:49.220Z', '2023-06-01T10:45:49.411Z', '2023-06-01T10:45:49.499Z', '2023-06-01T10:45:49.720Z', '2023-06-01T10:45:49.881Z', '2023-06-01T10:45:50.426Z', '2023-06-01T10:45:50.681Z', '2023-06-01T10:45:50.897Z', '2023-06-01T10:45:51.107Z', '2023-06-01T10:45:51.352Z', '2023-06-01T10:45:52.626Z', '2023-06-01T10:45:52.976Z', '2023-06-01T10:45:53.279Z', '2023-06-01T10:45:53.562Z', '2023-06-01T10:45:54.978Z', '2023-06-01T10:45:55.207Z', '2023-06-01T10:45:55.479Z', '2023-06-01T10:45:55.617Z', '2023-06-01T10:45:55.769Z', '2023-06-01T10:45:55.919Z', '2023-06-01T10:45:56.109Z', '2023-06-01T10:45:56.298Z', '2023-06-01T10:45:56.952Z', '2023-06-01T10:45:58.218Z', '2023-06-01T10:45:58.660Z', '2023-06-01T10:45:58.962Z', '2023-06-01T10:45:59.163Z', '2023-06-01T10:46:01.306Z', '2023-06-01T10:46:01.488Z', '2023-06-01T10:46:02.594Z', '2023-06-01T10:46:02.905Z', '2023-06-01T10:46:04.323Z', '2023-06-01T10:46:09.284Z', '2023-06-01T10:46:12.481Z', '2023-06-01T10:46:13.529Z', '2023-06-01T10:46:13.953Z', '2023-06-01T10:46:14.202Z', '2023-06-01T10:46:14.586Z', '2023-06-01T10:46:15.193Z', '2023-06-01T10:46:15.325Z', '2023-06-01T10:46:15.490Z', '2023-06-01T10:46:15.650Z', '2023-06-01T10:46:15.865Z', '2023-06-01T10:46:16.174Z', '2023-06-01T10:46:16.514Z', '2023-06-01T10:46:16.876Z', '2023-06-01T10:46:18.835Z', '2023-06-01T10:46:18.955Z', '2023-06-01T10:46:19.234Z', '2023-06-01T10:46:19.425Z', '2023-06-01T10:46:19.641Z', '2023-06-01T10:46:19.779Z', '2023-06-01T10:46:20.085Z', '2023-06-01T10:46:20.336Z', '2023-06-01T10:46:20.554Z', '2023-06-01T10:46:20.689Z', '2023-06-01T10:46:20.913Z', '2023-06-01T10:46:21.161Z', '2023-06-01T10:46:22.155Z', '2023-06-01T10:46:22.404Z', '2023-06-01T10:46:23.763Z', '2023-06-01T10:46:26.402Z', '2023-06-01T10:46:26.777Z', '2023-06-01T10:46:27.106Z', '2023-06-01T10:46:27.915Z', '2023-06-01T10:46:28.062Z', '2023-06-01T10:46:28.217Z', '2023-06-01T10:46:28.443Z', '2023-06-01T10:46:28.838Z', '2023-06-01T10:46:29.126Z', '2023-06-01T10:46:29.290Z', '2023-06-01T10:46:29.472Z', '2023-06-01T10:46:29.585Z', '2023-06-01T10:46:29.783Z', '2023-06-01T10:46:29.923Z', '2023-06-01T10:46:30.129Z', '2023-06-01T10:46:30.345Z', '2023-06-01T10:46:30.489Z', '2023-06-01T10:46:30.634Z', '2023-06-01T10:46:30.837Z', '2023-06-01T10:46:31.025Z', '2023-06-01T10:46:31.224Z', '2023-06-01T10:46:31.433Z', '2023-06-01T10:46:31.607Z', '2023-06-01T10:46:31.780Z', '2023-06-01T10:46:31.929Z', '2023-06-01T10:46:32.062Z', '2023-06-01T10:46:32.295Z', '2023-06-01T10:46:32.426Z', '2023-06-01T10:46:33.169Z', '2023-06-01T10:46:38.797Z', '2023-06-01T10:46:40.442Z', '2023-06-01T10:46:40.577Z', '2023-06-01T10:46:40.912Z', '2023-06-01T10:46:41.084Z', '2023-06-01T10:46:41.279Z', '2023-06-01T10:46:41.386Z', '2023-06-01T10:46:41.557Z', '2023-06-01T10:46:41.770Z', '2023-06-01T10:46:42.002Z', '2023-06-01T10:46:42.126Z', '2023-06-01T10:46:42.325Z', '2023-06-01T10:46:42.466Z', '2023-06-01T10:46:42.586Z', '2023-06-01T10:46:42.804Z', '2023-06-01T10:46:43.009Z', '2023-06-01T10:46:43.192Z', '2023-06-01T10:46:43.650Z', '2023-06-01T10:46:43.920Z', '2023-06-01T10:46:44.080Z', '2023-06-01T10:46:44.200Z', '2023-06-01T10:46:44.343Z', '2023-06-01T10:46:44.519Z', '2023-06-01T10:46:44.708Z', '2023-06-01T10:46:44.953Z', '2023-06-01T10:46:45.124Z', '2023-06-01T10:46:45.379Z', '2023-06-01T10:46:45.589Z', '2023-06-01T10:46:45.720Z', '2023-06-01T10:46:45.922Z', '2023-06-01T10:46:46.126Z', '2023-06-01T10:46:46.289Z', '2023-06-01T10:46:46.485Z', '2023-06-01T10:46:46.744Z', '2023-06-01T10:46:46.961Z', '2023-06-01T10:46:47.897Z', '2023-06-01T10:46:48.224Z', '2023-06-01T10:46:48.480Z', '2023-06-01T10:46:49.478Z', '2023-06-01T10:46:49.650Z', '2023-06-01T10:46:49.856Z', '2023-06-01T10:46:50.073Z', '2023-06-01T10:46:50.345Z', '2023-06-01T10:46:50.512Z', '2023-06-01T10:46:50.643Z', '2023-06-01T10:46:50.825Z', '2023-06-01T10:46:51.056Z', '2023-06-01T10:46:51.167Z', '2023-06-01T10:46:51.254Z', '2023-06-01T10:46:52.097Z', '2023-06-01T10:46:53.098Z', '2023-06-01T10:46:53.306Z', '2023-06-01T10:46:53.585Z', '2023-06-01T10:46:55.127Z', '2023-06-01T10:46:55.723Z', '2023-06-01T10:46:55.938Z', '2023-06-01T10:46:57.028Z', '2023-06-01T10:46:58.347Z', '2023-06-01T10:46:58.468Z', '2023-06-01T10:46:58.575Z', '2023-06-01T10:46:58.876Z', '2023-06-01T10:46:58.992Z', '2023-06-01T10:46:59.194Z', '2023-06-01T10:47:00.644Z', '2023-06-01T10:47:01.730Z', '2023-06-01T10:47:01.823Z', '2023-06-01T10:47:02.073Z', '2023-06-01T10:47:02.224Z', '2023-06-01T10:47:02.472Z', '2023-06-01T10:47:02.688Z', '2023-06-01T10:47:02.909Z', '2023-06-01T10:47:03.114Z', '2023-06-01T10:47:03.264Z', '2023-06-01T10:47:03.378Z', '2023-06-01T10:47:03.536Z', '2023-06-01T10:47:03.666Z', '2023-06-01T10:47:03.865Z', '2023-06-01T10:47:04.386Z', '2023-06-01T10:47:04.673Z', '2023-06-01T10:47:04.976Z', '2023-06-01T10:47:05.217Z', '2023-06-01T10:47:05.379Z', '2023-06-01T10:47:05.569Z', '2023-06-01T10:47:05.789Z', '2023-06-01T10:47:05.977Z', '2023-06-01T10:47:06.226Z', '2023-06-01T10:47:06.448Z', '2023-06-01T10:47:06.798Z', '2023-06-01T10:47:07.016Z', '2023-06-01T10:47:07.220Z', '2023-06-01T10:47:07.384Z', '2023-06-01T10:47:07.615Z', '2023-06-01T10:47:09.089Z', '2023-06-01T10:47:10.570Z', '2023-06-01T10:47:10.765Z', '2023-06-01T10:47:10.946Z', '2023-06-01T10:47:11.203Z', '2023-06-01T10:47:11.295Z', '2023-06-01T10:47:11.496Z', '2023-06-01T10:47:13.009Z', '2023-06-01T10:47:13.211Z', '2023-06-01T10:47:13.383Z', '2023-06-01T10:47:13.538Z', '2023-06-01T10:47:13.664Z', '2023-06-01T10:47:13.831Z', '2023-06-01T10:47:13.972Z', '2023-06-01T10:47:14.141Z', '2023-06-01T10:47:14.296Z', '2023-06-01T10:47:14.423Z', '2023-06-01T10:47:14.576Z', '2023-06-01T10:47:14.797Z', '2023-06-01T10:47:14.939Z', '2023-06-01T10:47:15.097Z', '2023-06-01T10:47:15.202Z', '2023-06-01T10:47:15.357Z', '2023-06-01T10:47:15.619Z', '2023-06-01T10:47:15.852Z', '2023-06-01T10:47:16.068Z', '2023-06-01T10:47:16.545Z', '2023-06-01T10:47:16.792Z', '2023-06-01T10:47:17.081Z', '2023-06-01T10:47:17.290Z', '2023-06-01T10:47:17.477Z', '2023-06-01T10:47:17.905Z', '2023-06-01T10:47:18.162Z', '2023-06-01T10:47:18.353Z', '2023-06-01T10:47:18.568Z', '2023-06-01T10:47:18.761Z', '2023-06-01T10:47:19.034Z', '2023-06-01T10:47:19.375Z', '2023-06-01T10:47:19.514Z', '2023-06-01T10:47:19.680Z', '2023-06-01T10:47:19.892Z', '2023-06-01T10:47:24.918Z', '2023-06-01T10:47:25.112Z', '2023-06-01T10:47:25.249Z', '2023-06-01T10:47:25.441Z', '2023-06-01T10:47:25.627Z', '2023-06-01T10:47:25.889Z', '2023-06-01T10:47:26.188Z', '2023-06-01T10:47:26.704Z', '2023-06-01T10:47:27.585Z', '2023-06-01T10:47:28.073Z', '2023-06-01T10:47:28.474Z', '2023-06-01T10:47:29.729Z', '2023-06-01T10:47:29.896Z', '2023-06-01T10:47:30.088Z', '2023-06-01T10:47:30.232Z', '2023-06-01T10:47:30.442Z', '2023-06-01T10:47:30.633Z', '2023-06-01T10:47:30.770Z', '2023-06-01T10:47:30.953Z', '2023-06-01T10:47:31.159Z', '2023-06-01T10:47:31.282Z', '2023-06-01T10:47:31.362Z', '2023-06-01T10:47:31.576Z', '2023-06-01T10:47:32.417Z', '2023-06-01T10:47:32.658Z', '2023-06-01T10:47:32.853Z', '2023-06-01T10:47:33.678Z', '2023-06-01T10:47:34.001Z', '2023-06-01T10:47:34.193Z', '2023-06-01T10:47:34.358Z', '2023-06-01T10:47:35.506Z', '2023-06-01T10:47:35.748Z', '2023-06-01T10:47:35.924Z', '2023-06-01T10:47:35.961Z', '2023-06-01T10:47:36.593Z', '2023-06-01T10:47:36.769Z', '2023-06-01T10:47:36.954Z', '2023-06-01T10:47:38.979Z', '2023-06-01T10:47:41.692Z', '2023-06-01T10:47:41.833Z', '2023-06-01T10:47:41.976Z', '2023-06-01T10:47:42.170Z', '2023-06-01T10:47:42.416Z', '2023-06-01T10:47:42.548Z', '2023-06-01T10:47:42.759Z', '2023-06-01T10:47:42.962Z', '2023-06-01T10:47:43.155Z', '2023-06-01T10:47:43.857Z', '2023-06-01T10:47:44.081Z', '2023-06-01T10:47:44.258Z', '2023-06-01T10:47:45.282Z', '2023-06-01T10:47:47.083Z', '2023-06-01T10:47:47.514Z', '2023-06-01T10:47:47.761Z', '2023-06-01T10:47:48.018Z', '2023-06-01T10:47:48.233Z', '2023-06-01T10:47:48.415Z', '2023-06-01T10:47:48.560Z', '2023-06-01T10:47:48.730Z', '2023-06-01T10:47:48.905Z', '2023-06-01T10:47:49.131Z', '2023-06-01T10:47:49.337Z', '2023-06-01T10:47:49.601Z', '2023-06-01T10:47:49.849Z', '2023-06-01T10:47:50.026Z', '2023-06-01T10:47:50.218Z', '2023-06-01T10:47:50.453Z', '2023-06-01T10:47:50.667Z', '2023-06-01T10:47:52.467Z', '2023-06-01T10:47:53.321Z', '2023-06-01T10:47:53.507Z', '2023-06-01T10:47:56.586Z', '2023-06-01T10:47:56.793Z', '2023-06-01T10:47:58.066Z', '2023-06-01T10:47:58.353Z', '2023-06-01T10:47:58.498Z', '2023-06-01T10:47:58.714Z', '2023-06-01T10:47:58.841Z', '2023-06-01T10:47:59.008Z', '2023-06-01T10:47:59.176Z', '2023-06-01T10:47:59.390Z', '2023-06-01T10:47:59.529Z', '2023-06-01T10:47:59.720Z', '2023-06-01T10:47:59.960Z', '2023-06-01T10:48:00.184Z', '2023-06-01T10:48:01.273Z', '2023-06-01T10:48:01.445Z', '2023-06-01T10:48:01.599Z', '2023-06-01T10:48:01.729Z', '2023-06-01T10:48:01.905Z', '2023-06-01T10:48:02.217Z', '2023-06-01T10:48:02.787Z', '2023-06-01T10:48:02.968Z', '2023-06-01T10:48:03.111Z', '2023-06-01T10:48:03.321Z', '2023-06-01T10:48:03.497Z', '2023-06-01T10:48:03.644Z', '2023-06-01T10:48:03.850Z', '2023-06-01T10:48:04.264Z', '2023-06-01T10:48:04.565Z', '2023-06-01T10:48:04.818Z', '2023-06-01T10:48:05.025Z', '2023-06-01T10:48:05.237Z', '2023-06-01T10:48:05.405Z', '2023-06-01T10:48:05.614Z', '2023-06-01T10:48:06.392Z', '2023-06-01T10:48:06.649Z', '2023-06-01T10:48:07.002Z', '2023-06-01T10:48:07.346Z', '2023-06-01T10:48:07.549Z', '2023-06-01T10:48:07.735Z', '2023-06-01T10:48:07.967Z', '2023-06-01T10:48:08.155Z', '2023-06-01T10:48:08.376Z', '2023-06-01T10:48:08.585Z', '2023-06-01T10:48:08.731Z', '2023-06-01T10:48:08.995Z', '2023-06-01T10:48:09.139Z', '2023-06-01T10:48:09.337Z', '2023-06-01T10:48:09.552Z', '2023-06-01T10:48:10.473Z', '2023-06-01T10:48:24.342Z', '2023-06-01T10:48:26.908Z', '2023-06-01T10:48:35.773Z', '2023-06-01T10:48:37.489Z', '2023-06-01T10:48:37.613Z', '2023-06-01T10:48:38.226Z', '2023-06-01T10:48:38.408Z', '2023-06-01T10:48:38.531Z', '2023-06-01T10:48:38.698Z', '2023-06-01T10:48:38.907Z', '2023-06-01T10:48:39.136Z', '2023-06-01T10:48:39.352Z', '2023-06-01T10:48:39.556Z', '2023-06-01T10:48:39.658Z', '2023-06-01T10:48:39.858Z', '2023-06-01T10:48:40.089Z', '2023-06-01T10:48:40.280Z', '2023-06-01T10:48:40.436Z', '2023-06-01T10:48:40.634Z', '2023-06-01T10:48:40.795Z', '2023-06-01T10:48:41.064Z', '2023-06-01T10:48:41.239Z', '2023-06-01T10:48:41.372Z', '2023-06-01T10:48:41.513Z', '2023-06-01T10:48:41.655Z', '2023-06-01T10:48:41.930Z', '2023-06-01T10:48:42.218Z', '2023-06-01T10:48:42.472Z', '2023-06-01T10:48:42.634Z', '2023-06-01T10:48:42.857Z', '2023-06-01T10:48:43.062Z', '2023-06-01T10:48:43.225Z', '2023-06-01T10:48:43.435Z', '2023-06-01T10:48:43.648Z', '2023-06-01T10:48:43.888Z', '2023-06-01T10:48:44.056Z', '2023-06-01T10:48:44.256Z', '2023-06-01T10:48:45.071Z', '2023-06-01T10:48:45.472Z', '2023-06-01T10:48:45.681Z', '2023-06-01T10:48:45.947Z', '2023-06-01T10:48:46.437Z', '2023-06-01T10:48:46.625Z', '2023-06-01T10:48:46.889Z', '2023-06-01T10:48:47.160Z', '2023-06-01T10:48:47.338Z', '2023-06-01T10:48:50.026Z', '2023-06-01T10:48:50.162Z', '2023-06-01T10:48:50.449Z', '2023-06-01T10:48:52.098Z', '2023-06-01T10:48:52.315Z', '2023-06-01T10:48:52.505Z', '2023-06-01T10:48:52.680Z', '2023-06-01T10:48:52.851Z', '2023-06-01T10:48:53.673Z', '2023-06-01T10:48:53.800Z', '2023-06-01T10:48:53.897Z', '2023-06-01T10:48:54.107Z', '2023-06-01T10:48:54.315Z', '2023-06-01T10:48:54.506Z', '2023-06-01T10:48:54.650Z', '2023-06-01T10:48:54.794Z', '2023-06-01T10:48:54.907Z', '2023-06-01T10:48:55.072Z', '2023-06-01T10:48:55.212Z', '2023-06-01T10:48:55.472Z', '2023-06-01T10:48:56.084Z', '2023-06-01T10:48:56.225Z', '2023-06-01T10:48:56.421Z', '2023-06-01T10:48:56.613Z', '2023-06-01T10:48:56.832Z', '2023-06-01T10:48:57.122Z', '2023-06-01T10:48:57.220Z', '2023-06-01T10:48:57.897Z', '2023-06-01T10:48:58.073Z', '2023-06-01T10:48:58.272Z', '2023-06-01T10:48:58.491Z', '2023-06-01T10:48:58.745Z', '2023-06-01T10:48:59.240Z', '2023-06-01T10:48:59.457Z', '2023-06-01T10:48:59.596Z', '2023-06-01T10:48:59.724Z', '2023-06-01T10:48:59.842Z', '2023-06-01T10:49:00.004Z', '2023-06-01T10:49:00.096Z', '2023-06-01T10:49:00.265Z', '2023-06-01T10:49:00.426Z', '2023-06-01T10:49:00.636Z', '2023-06-01T10:49:00.833Z', '2023-06-01T10:49:01.009Z', '2023-06-01T10:49:01.209Z', '2023-06-01T10:49:01.375Z', '2023-06-01T10:49:01.489Z', '2023-06-01T10:49:01.649Z', '2023-06-01T10:49:01.845Z', '2023-06-01T10:49:02.116Z', '2023-06-01T10:49:02.363Z', '2023-06-01T10:49:02.722Z', '2023-06-01T10:49:03.136Z', '2023-06-01T10:49:03.689Z', '2023-06-01T10:49:03.913Z', '2023-06-01T10:49:04.153Z', '2023-06-01T10:49:04.394Z', '2023-06-01T10:49:09.596Z', '2023-06-01T10:49:09.889Z', '2023-06-01T10:49:09.985Z', '2023-06-01T10:49:10.131Z', '2023-06-01T10:49:10.405Z', '2023-06-01T10:49:10.554Z', '2023-06-01T10:49:10.760Z', '2023-06-01T10:49:10.953Z', '2023-06-01T10:49:11.092Z', '2023-06-01T10:49:11.304Z', '2023-06-01T10:49:11.430Z', '2023-06-01T10:49:11.586Z', '2023-06-01T10:49:11.848Z', '2023-06-01T10:49:11.961Z', '2023-06-01T10:49:12.337Z']","The Norwegian breast-cancer screening program was started in 1996.  Women between the ages 50 and 69 years were offered screening mammography every 2 years. we compared the incidence-based rates of death from breast cancer in four groups: two groups of women who from 1996 through 2005 living in counties with screening or without screening and two historical-comparison groups that from 1986 through 1995.
We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,00 person-years in the screening group compared with historical screening group and by 4.8 deaths per 100,000 person-years in non screening group as compared with historical non screening group.
The availability of screening mammography was associated with a reduction in the rate of death from breast cancer.",False,real
3XABXM4AJ1Q8DQKOXVSS6QS7TGU8QF,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
",copy Control V paste,"[None, '2023-06-01T06:39:50.070Z', '2023-06-01T06:39:50.373Z', None]","This study examined the effect of screening mammography on mortality from breast cancer in Norway. 40,075 women with breast cancer were analysed. It was found that the rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group, and 4.8 deaths per 100,000 person-years in the nonscreening group, compared to their historical counterparts. This suggests that the mortality rate was improved in both screening and nonscreening groups, either due to awareness and treatment advances, or because of the availability of screening. However, the screening itself was estimated to account for only one-third of the total reduction.",True,synthetic
3XABXM4AJ1Q8DQKOXVSS6QS7TGU8QF,"Effect of Screening Mammography on Breast-Cancer Mortality in Norway

A challenge in quantifying the effect of screening mammography on breast-cancer mortality is to provide valid comparison groups. The use of historical control subjects does not take into account chronologic trends associated with advances in breast-cancer awareness and treatment.

The Norwegian breast-cancer screening program was started in 1996 and expanded geographically during the subsequent 9 years. Women between the ages of 50 and 69 years were offered screening mammography every 2 years. We compared the incidence-based rates of death from breast cancer in four groups; two groups of women who from 1996 through 2005 were living in counties with screening (screening group) or without screening (nonscreening group); and two historical-comparison groups that from 1986 through 1995 mirrored the current groups.

We analyzed data from 40,075 women with breast cancer. The rate of death was reduced by 7.2 deaths per 100,000 person-years in the screening group as compared with the historical screening group (rate ratio, 0.72; 95% confidence interval (CI), 0.63 to 0.81) and by 4.8 deaths per 100,000 person-years in the nonscreening group as compared with the historical nonscreening group (rate ratio, 0.82; 95% CI, 0.71 to 0.93; P (0.001 for both comparisons), for a relative reduction in mortality of 10% in the screening group (P = 0.13). Thus, the difference in the reduction in mortality between the current and historical groups that could be attributed to screening alone was 2.4 deaths per 100,000 person-years, or a third of the total reduction of 7.2 deaths.

The availability of screening mammography was associated with a reduction in the rate of death from breast cancer, but the screening itself accounted for only about a third of the total reduction.
",copy paste Control v paste,"[None, None, '2023-06-01T06:40:06.904Z', '2023-06-01T06:40:07.209Z', None]","The effect of screening mammography on breast cancer mortality was investigated in a Norwegian research. The difficult part of these investigations is creating reliable comparison groups. Two groups of women who had access to screening mammography and two historical reference groups were used by the researchers to compare the death rates from breast cancer in this case. The examination of the data comprised 40,075 breast cancer survivors. According to the findings, the screening group's mortality rate was lower than the historical screening group's by 7.2 deaths per 100,000 person-years. Similar to the historical nonscreening group, the nonscreening group's death rate was decreased by 4.8 deaths per 100,000 person-years. But the study discovered that only approximately a third was attributable to the screening itself.",True,synthetic
3BFF0DJK8XX3OQRPSXSSSM3VPHZTSD,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
",copy copy CapsLock Shift Control V paste,"[None, None, '2023-06-01T16:28:11.659Z', '2023-06-01T16:28:11.689Z', '2023-06-01T16:28:12.943Z', '2023-06-01T16:28:13.355Z', None]"," Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS,",True,real
3BFF0DJK8XX3OQRPSXSSSM3VPHZTSD,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
",copy Control v paste,"[None, '2023-06-01T06:44:19.371Z', '2023-06-01T06:44:19.723Z', None]","The first results of a phase 3 trial for the RTS,S/AS01 malaria vaccine in African children have been reported. The study enrolled 15,460 children in two age groups, 6 to 12 weeks and 5 to 17 months, and compared the efficacy, safety, and immunogenicity of the vaccine to a non-malaria comparator vaccine. The analysis focused on the first 6,000 children in the older age group who received all three doses of the vaccine. The results showed that the RTS,S/AS01 vaccine had an efficacy of 50.4% against clinical malaria and 45.1% against severe malaria in the intention-to-treat population. In the per-protocol population, the efficacy was even higher at 55.8% against clinical malaria and 47.3% against severe malaria. The vaccine also had a similar safety profile to the control group, with no significant differences in adverse events. Overall, the study demonstrates that the RTS,S/AS01 vaccine provides protection against both clinical and severe malaria in African children.",True,synthetic
3BFF0DJK8XX3OQRPSXSSSM3VPHZTSD,"First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries.

From March 2009 through January 2011, we enrolled 15,460 children in two age categories - 6 to 12 weeks of age and 5 to 17 months of age - for vaccination with either RTS, S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol. After 250 children had an episode of severe malaria, we evaluated vaccine efficacy against severe malaria in both age categories.

In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol population during an average follow-up of 11 months. Serious adverse events occurred with a similar frequency in the two study groups. Among children in the older age category, the rate of generalized convulsive seizures after RTS, S/AS01 vaccination was 1.04 per 1000 doses (95% CI, 0.62 to 1.64).

The RTS, S/AS01 vaccine provided protection against both clinical and severe malaria in African children.
",copy paste,"[None, None]","
In the 14 months after the first dose of vaccine, the incidence of first episodes of clinical malaria in the first 6000 children in the older age category was 0.32 episodes per person-year in the RTS, S/AS01 group and 0.55 episodes per person-year in the control group, for an efficacy of 50.4% (95% confidence interval (CI), 45.8 to 54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) in the per-protocol population. Vaccine efficacy against severe malaria in the combined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-",True,real
3CESM1J3EIOQT9XMGPU0E1E2BMKW6K,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",copy Control V paste,"[None, '2023-06-01T06:39:08.321Z', '2023-06-01T06:39:08.554Z', None]","In this study, a Tennessee Medicaid cohort was used to assess the risk of cardiovascular death related to azithromycin and other antibiotics such as amoxicillin, ciprofloxacin, and levofloxacin, excluding patients with serious non-cardiovascular illness and person-time during and shortly after hospitalization. Results showed that during 5 days of azithromycin therapy, there was an increased risk of cardiovascular death (2.88 times) and death from any cause (1.85 times) compared to those who took no antibiotics. Amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an estimated 47 additional cardiovascular deaths per 1 million courses, with a much higher number of 245 additional cardiovascular deaths per 1 million courses among patients in the highest decile of risk for cardiovascular disease. The risk of cardiovascular death was higher with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin. These findings suggest that azithromycin should be used with caution, especially in patients with high risk of cardiovascular disease.",True,synthetic
3CESM1J3EIOQT9XMGPU0E1E2BMKW6K,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",copy paste copy \ Backspace Backspace Control v paste,"[None, None, None, '2023-06-01T12:07:33.534Z', '2023-06-01T12:07:35.448Z', '2023-06-01T12:07:36.080Z', '2023-06-01T12:07:37.998Z', '2023-06-01T12:07:38.478Z', '2023-06-01T12:07:38.965Z', None, '2023-06-01T12:07:39.936Z']","During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death. Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.
",True,real
3CESM1J3EIOQT9XMGPU0E1E2BMKW6K,"Azithromycin and the Risk of Cardiovascular Death

Although several macrolide antibiotics are proarrhythmic and associated with an increased risk of sudden cardiac death, azithromycin is thought to have minimal cardiotoxicity. However, published reports of arrhythmias suggest that azithromycin may increase the risk of cardiovascular death.

We studied a Tennessee Medicaid cohort designed to detect an increased risk of death related to short-term cardiac effects of medication, excluding patients with serious noncardiovascular illness and person-time during and shortly after hospitalization. The cohort included patients who took azithromycin (347,795 prescriptions), propensity-score - matched persons who took no antibiotics (1,391,180 control periods), and patients who took amoxicillin (1,348,672 prescriptions), ciprofloxacin (264,626 prescriptions), or levofloxacin (193,906 prescriptions).

During 5 days of therapy, patients taking azithromycin, as compared with those who took no antibiotics, had an increased risk of cardiovascular death (hazard ratio, 2.88; 95% confidence interval (CI), 1.79 to 4.63; P (0.001) and death from any cause (hazard ratio, 1.85; 95% CI, 1.25 to 2.75; P = 0.002). Patients who took amoxicillin had no increase in the risk of death during this period. Relative to amoxicillin, azithromycin was associated with an increased risk of cardiovascular death (hazard ratio, 2.49; 95% CI, 1.38 to 4.50; P = 0.002) and death from any cause (hazard ratio, 2.02; 95% CI, 1.24 to 3.30; P = 0.005), with an estimated 47 additional cardiovascular deaths per 1 million courses; patients in the highest decile of risk for cardiovascular disease had an estimated 245 additional cardiovascular deaths per 1 million courses. The risk of cardiovascular death was significantly greater with azithromycin than with ciprofloxacin but did not differ significantly from that with levofloxacin.

During 5 days of azithromycin therapy, there was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease.
",copy Control V paste,"[None, '2023-06-01T06:40:30.604Z', '2023-06-01T06:40:30.931Z', None]","In a study of a Tennessee Medicaid cohort, it was found that patients taking azithromycin were at an increased risk of cardiovascular death and death from any cause within 5 days of starting the medication. This risk was 2.88 and 1.85 times higher respectively, when compared with patients who took no antibiotics. Furthermore, the risk of cardiovascular death was significantly higher with azithromycin than with ciprofloxacin, with an estimated 47 additional cardiovascular deaths per million courses. This risk was particularly pronounced among those with the highest baseline risk of cardiovascular disease (estimated 245 additional cardiovascular deaths per million courses). As a result, the study suggests that caution should be taken when prescribing azithromycin, especially for those with an existing cardiovascular risk.",True,synthetic
3BA7SXOG1JB8PRZOAAHSBG2CP2W8RG,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",Control Control C copy Control V paste Control C copy Control V paste Control Control Control Control Control C copy Control V paste,"['2023-06-01T06:35:13.434Z', '2023-06-01T06:40:40.140Z', '2023-06-01T06:40:40.604Z', None, '2023-06-01T06:40:41.820Z', '2023-06-01T06:40:42.235Z', None, '2023-06-01T06:40:42.563Z', '2023-06-01T06:40:55.972Z', '2023-06-01T06:40:56.443Z', None, '2023-06-01T06:40:58.277Z', '2023-06-01T06:40:58.653Z', None, '2023-06-01T06:41:00.101Z', '2023-06-01T06:41:00.341Z', '2023-06-01T06:41:29.124Z', '2023-06-01T06:41:29.628Z', '2023-06-01T06:41:29.666Z', '2023-06-01T06:41:29.693Z', '2023-06-01T06:41:29.723Z', '2023-06-01T06:41:29.724Z', None, '2023-06-01T06:41:31.957Z', '2023-06-01T06:41:32.212Z', None]","The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02).  The primary end point was the time from randomization to the first occurrence of a primary outcome event",True,real
3BA7SXOG1JB8PRZOAAHSBG2CP2W8RG,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",copy paste,"[None, None]","The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02).",True,synthetic
3BA7SXOG1JB8PRZOAAHSBG2CP2W8RG,"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established.

We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death).

The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P = 0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P = 0.03). The rates of cardiovascular death and death from any cause were not increased.

Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause.
",copy paste,"[None, None]","The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2 / 1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval (CI), 1.03 to 1.31; P = 0.02).",True,synthetic
3H5TOKO3D94EK7E26JOHJ9VBRTM649,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
",copy Control v paste,"[None, '2023-06-01T06:38:49.452Z', '2023-06-01T06:38:49.747Z', None]","In a randomized, placebo-controlled, double-blind study of exemestane, 4560 postmenopausal women between the age of 35 and above considered to be at a moderately increased risk for breast cancer were given the drug or a placebo. After a median follow-up period of 3 years, exemestane was found to reduce the incidence of invasive breast cancer by 65% compared to the placebo group. Furthermore, the relative risk of both invasive and non-invasive breast cancer was significantly reduced. Despite a slight increase in adverse events, there were no significant differences in terms of skeletal fractures, cardiovascular events, other cancers or treatment-related deaths between the two groups. The use of exemestane appeared to be safe and had no major effect on health-related quality of life.",True,synthetic
3H5TOKO3D94EK7E26JOHJ9VBRTM649,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
",paste paste,"[None, None]","The benefits of medicines are the helpful effects you get when you use them, such as lowering blood pressure, curing infection, or relieving pain. The risks of medicines are the chances that something 
But let us now turn to the names of our profession and, of those who practice it. The word medicine comes to us from the Latin medicina, the verb root of which is mederi, to heal, a thoroughly respectable derivationunwanted or unexpected could happen to you when you use them.",True,real
3H5TOKO3D94EK7E26JOHJ9VBRTM649,"Exemestane for Breast-Cancer Prevention in Postmenopausal Women

Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.

In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65% relative reduction in invasive breast cancer, eligible postmenopausal women 35 years of age or older had at least one of the following risk factors; 60 years of age or older; Gail 5-year risk score greater than 1.66% (chances in 100 of invasive breast cancer developing within 5 years); prior atypical ductal or lobular hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy. Toxic effects and health-related and menopause-specific qualities of life were measured.

A total of 4560 women for whom the median age was 62.5 years and the median Gail risk score was 2.3% were randomly assigned to either exemestane or placebo. At a median follow-up of 35 months, 11 invasive breast cancers were detected in those given exemestane and in 32 of those given placebo, with a 65% relative reduction in the annual incidence of invasive breast cancer (0.19% vs. 0.55%; hazard ratio, 0.35; 95% confidence interval (CI), 0.18 to 0.70; P = 0.002). The annual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on exemestane and 0.77% on placebo (hazard ratio, 0.47; 95% CI, 0.27 to 0.79; P = 0.004). Adverse events occurred in 88% of the exemestane group and 85% of the placebo group (P = 0.003), with no significant differences between the two groups in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Minimal quality-of-life differences were observed.

Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer. During a median follow-up period of 3 years, exemestane was associated with no serious toxic effects and only minimal changes in health-related quality of life.
",copy Control v paste,"[None, '2023-06-01T06:38:07.727Z', '2023-06-01T06:38:08.106Z', None]","In this randomized, controlled trial of exemestane for reducing the risk of invasive breast cancer in 4560 postmenopausal women, exemestane was associated with a 65% reduction in invasive breast cancer incidence in comparison to placebo after a median follow-up of 35 months. Adverse events occurred in 88% of the exemestane group and 85% of the placebo group, with no significant differences in terms of skeletal fractures, cardiovascular events, other cancers, or treatment-related deaths. Further, the trial revealed minimal changes in health-related quality of life, indicating that exemestane may be an effective, well-tolerated primary-prevention option for postmenopausal women at moderately increased risk for breast cancer.",True,synthetic
3PUV2Q8SV4PXQFEQVL6IXTB9I7QBDC,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
",copy paste copy paste,"[None, None, None, None]","The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed. have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.",True,real
3PUV2Q8SV4PXQFEQVL6IXTB9I7QBDC,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
",Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control Control v paste,"['2023-06-01T06:55:12.775Z', '2023-06-01T06:55:13.284Z', '2023-06-01T06:55:13.316Z', '2023-06-01T06:55:13.347Z', '2023-06-01T06:55:13.378Z', '2023-06-01T06:55:13.410Z', '2023-06-01T06:55:13.442Z', '2023-06-01T06:55:13.474Z', '2023-06-01T06:55:13.521Z', '2023-06-01T06:55:13.552Z', '2023-06-01T06:55:13.584Z', '2023-06-01T06:55:13.616Z', '2023-06-01T06:55:13.647Z', '2023-06-01T06:55:13.677Z', '2023-06-01T06:55:13.709Z', '2023-06-01T06:55:13.740Z', '2023-06-01T06:55:13.758Z', None]","The inverse association between coffee consumption and mortality was consistent regardless of cumulative caffeine intake up to 2.5 g/d. Further associated factors such as reported diet, BMI, physical activity, smoking, were controlled for in the analysis. The National Institutes of Health-AARP Diet and Health Study collected detailed dietary and other lifestyle information from over 500,000 participants. This study adds to the evidence that coffee consumption might have beneficial health effects.",True,synthetic
3PUV2Q8SV4PXQFEQVL6IXTB9I7QBDC,"Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence

To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.

We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.

The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women - an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased by 8%, from 102 to 94 cases per 100,000 women - an absolute decrease of 8 cases per 100,000 women. With the assumption of a constant underlying disease burden, only 8 of the 122 additional early-stage cancers diagnosed were expected to progress to advanced disease. After excluding the transient excess incidence associated with hormone-replacement therapy and adjusting for trends in the incidence of breast cancer among women younger than 40 years of age, we estimated that breast cancer was overdiagnosed (i.e., tumors were detected on screening that would never have led to clinical symptoms) in 1.3 million U.S. women in the past 30 years. We estimated that in 2008, breast cancer was overdiagnosed in more than 70,000 women; this accounted for 31% of all breast cancers diagnosed.

Despite substantial increases in the number of cases of early-stage breast cancer detected, screening mammography has only marginally reduced the rate at which women present with advanced cancer. Although it is not certain which women have been affected, the imbalance suggests that there is substantial overdiagnosis, accounting for nearly a third of all newly diagnosed breast cancers, and that screening is having, at best, only a small effect on the rate of death from breast cancer.
",copy copy paste,"[None, None, None]","Screening mammography has been used in the United States since 1976 to detect breast cancer at an early, more curable stage. Data from Surveillance, Epidemiology, and End Results showed that its introduction has resulted in an absolute increase of 122 cases per 100,000 women in the incidence detected of early-stage breast cancer, and a concomitant absolute decrease of 8 cases per 100,000 women in the rate of late-stage breast cancer. However, after accounting for the transient excess due to hormone-replacement therapy, it was estimated that 1.3 million U.S. women have been overdiagnosed in the last 30 years, amounting to 31% of all breast cancers diagnosed in 2008 alone. Thus, while screening mammography has increased the number of early-stage cancer cases, its effect on reducing the rate of death from breast cancer has been minimal at best.",True,synthetic
3KTCJ4SCVGMZHB2B6HCWA7LU59R1M1,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",Control c copy c copy Control v paste Backspace Backspace Backspace Backspace Backspace Control v paste t h u i s Backspace Backspace Backspace Backspace Backspace,"['2023-06-01T08:54:38.070Z', '2023-06-01T08:54:38.285Z', None, '2023-06-01T08:54:38.456Z', None, '2023-06-01T08:57:41.376Z', '2023-06-01T08:57:41.702Z', None, '2023-06-01T08:58:02.966Z', '2023-06-01T08:58:03.334Z', '2023-06-01T08:58:04.918Z', '2023-06-01T08:58:05.129Z', '2023-06-01T08:58:05.357Z', '2023-06-01T08:58:30.639Z', '2023-06-01T08:58:31.013Z', None, '2023-06-01T08:58:35.631Z', '2023-06-01T08:58:36.471Z', '2023-06-01T08:58:36.714Z', '2023-06-01T08:58:36.966Z', '2023-06-01T08:58:36.989Z', '2023-06-01T08:58:37.221Z', '2023-06-01T08:58:37.777Z', '2023-06-01T08:58:37.857Z', '2023-06-01T08:58:38.021Z', '2023-06-01T08:58:38.207Z', '2023-06-01T08:58:39.668Z']",Primary prevention refers to the steps taken by an individual to prevent the onset of the disease. This is achieved by maintaining a healthy lifestyle choice such as diet and exercise. Secondary prevention focuses on reducing the impact of the disease by early diagnosis prior to any critical and permanent damage. ,True,real
3KTCJ4SCVGMZHB2B6HCWA7LU59R1M1,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",I T W A S Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace I CapsLock t w a s a d i e t p l a n f o r a g o o h e a l t h a n d a t r i a l i n a p a i n Backspace Backspace Backspace Backspace Backspace Backspace s p a i n t h e r e i s a Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace e r e i s a c a r d i o v a s c u l a Backspace r d i s e a s e t h a t a s o t h e Backspace a t t h e r y Backspace Backspace Backspace Backspace Backspace Backspace h Backspace Control Control Control z Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace i t w a s a d i e t p l a n f o r a g o o d h e a l t h a n d a t r i a l f o r m s p a i n t h e r e i s a c a d i o v a s u l a r d i s e a s e a t e n t r o l l m e n t s o t h a t h t h e r y m a i n t a i n a Backspace Backspace s i Backspace Backspace d i e Backspace t l Backspace p l a n r e d u c e d i e t e r y f a t i t m i x e d a o l i v e o i l a n d m i x e d n u t s s o t h a t i t w a s a g o o d h e a l t h f o r a d a y o f l i f e,"['2023-06-01T07:12:25.109Z', '2023-06-01T07:12:25.252Z', '2023-06-01T07:12:25.412Z', '2023-06-01T07:12:25.653Z', '2023-06-01T07:12:25.980Z', '2023-06-01T07:12:26.132Z', '2023-06-01T07:12:26.268Z', '2023-06-01T07:12:26.860Z', '2023-06-01T07:12:27.364Z', '2023-06-01T07:12:27.408Z', '2023-06-01T07:12:27.439Z', '2023-06-01T07:12:27.469Z', '2023-06-01T07:12:27.500Z', '2023-06-01T07:12:27.537Z', '2023-06-01T07:12:27.568Z', '2023-06-01T07:12:27.595Z', '2023-06-01T07:12:27.636Z', '2023-06-01T07:12:27.669Z', '2023-06-01T07:12:27.698Z', '2023-06-01T07:12:27.724Z', '2023-06-01T07:12:27.766Z', '2023-06-01T07:12:27.796Z', '2023-06-01T07:12:27.824Z', '2023-06-01T07:12:27.866Z', '2023-06-01T07:12:27.896Z', '2023-06-01T07:12:27.928Z', '2023-06-01T07:12:27.958Z', '2023-06-01T07:12:27.987Z', '2023-06-01T07:12:28.032Z', '2023-06-01T07:12:28.063Z', '2023-06-01T07:12:28.516Z', '2023-06-01T07:12:28.685Z', '2023-06-01T07:12:29.108Z', '2023-06-01T07:12:29.308Z', '2023-06-01T07:12:29.572Z', '2023-06-01T07:12:29.844Z', '2023-06-01T07:12:29.948Z', '2023-06-01T07:12:30.172Z', '2023-06-01T07:12:30.308Z', '2023-06-01T07:12:30.516Z', '2023-06-01T07:12:31.404Z', '2023-06-01T07:12:31.589Z', '2023-06-01T07:12:31.796Z', '2023-06-01T07:12:32.100Z', '2023-06-01T07:12:32.212Z', '2023-06-01T07:12:32.492Z', '2023-06-01T07:12:32.636Z', '2023-06-01T07:12:32.708Z', '2023-06-01T07:12:34.124Z', '2023-06-01T07:12:34.292Z', '2023-06-01T07:12:34.524Z', '2023-06-01T07:12:34.708Z', '2023-06-01T07:12:34.868Z', '2023-06-01T07:12:35.052Z', '2023-06-01T07:12:35.237Z', '2023-06-01T07:12:35.452Z', '2023-06-01T07:12:36.420Z', '2023-06-01T07:12:36.588Z', '2023-06-01T07:12:36.740Z', '2023-06-01T07:12:36.924Z', '2023-06-01T07:12:37.180Z', '2023-06-01T07:12:37.300Z', '2023-06-01T07:12:37.532Z', '2023-06-01T07:12:37.692Z', '2023-06-01T07:12:37.996Z', '2023-06-01T07:12:38.172Z', '2023-06-01T07:12:38.356Z', '2023-06-01T07:12:43.692Z', '2023-06-01T07:12:43.844Z', '2023-06-01T07:12:43.972Z', '2023-06-01T07:12:44.124Z', '2023-06-01T07:12:44.332Z', '2023-06-01T07:12:44.469Z', '2023-06-01T07:12:45.516Z', '2023-06-01T07:12:45.652Z', '2023-06-01T07:12:45.868Z', '2023-06-01T07:12:46.076Z', '2023-06-01T07:12:46.196Z', '2023-06-01T07:12:46.404Z', '2023-06-01T07:12:47.291Z', '2023-06-01T07:12:47.484Z', '2023-06-01T07:12:47.668Z', '2023-06-01T07:12:48.308Z', '2023-06-01T07:12:48.500Z', '2023-06-01T07:12:48.813Z', '2023-06-01T07:12:49.108Z', '2023-06-01T07:12:49.340Z', '2023-06-01T07:12:49.556Z', '2023-06-01T07:12:50.140Z', '2023-06-01T07:12:50.324Z', '2023-06-01T07:12:50.500Z', '2023-06-01T07:12:50.660Z', '2023-06-01T07:12:50.821Z', '2023-06-01T07:12:51.452Z', '2023-06-01T07:12:51.900Z', '2023-06-01T07:12:52.083Z', '2023-06-01T07:12:52.227Z', '2023-06-01T07:12:52.483Z', '2023-06-01T07:12:52.707Z', '2023-06-01T07:12:52.907Z', '2023-06-01T07:12:58.564Z', '2023-06-01T07:12:58.732Z', '2023-06-01T07:12:59.004Z', '2023-06-01T07:12:59.163Z', '2023-06-01T07:12:59.331Z', '2023-06-01T07:12:59.676Z', '2023-06-01T07:12:59.980Z', '2023-06-01T07:13:00.140Z', '2023-06-01T07:13:00.331Z', '2023-06-01T07:13:00.508Z', '2023-06-01T07:13:00.715Z', '2023-06-01T07:13:01.683Z', '2023-06-01T07:13:01.843Z', '2023-06-01T07:13:02.003Z', '2023-06-01T07:13:02.155Z', '2023-06-01T07:13:02.315Z', '2023-06-01T07:13:02.475Z', '2023-06-01T07:13:02.635Z', '2023-06-01T07:13:02.788Z', '2023-06-01T07:13:02.939Z', '2023-06-01T07:13:04.259Z', '2023-06-01T07:13:04.436Z', '2023-06-01T07:13:04.612Z', '2023-06-01T07:13:04.828Z', '2023-06-01T07:13:05.100Z', '2023-06-01T07:13:05.332Z', '2023-06-01T07:13:05.468Z', '2023-06-01T07:13:05.644Z', '2023-06-01T07:13:05.859Z', '2023-06-01T07:13:06.668Z', '2023-06-01T07:13:06.803Z', '2023-06-01T07:13:07.163Z', '2023-06-01T07:13:07.531Z', '2023-06-01T07:13:08.515Z', '2023-06-01T07:13:08.627Z', '2023-06-01T07:13:09.435Z', '2023-06-01T07:13:09.644Z', '2023-06-01T07:13:09.843Z', '2023-06-01T07:13:11.605Z', '2023-06-01T07:13:11.805Z', '2023-06-01T07:13:12.045Z', '2023-06-01T07:13:12.237Z', '2023-06-01T07:13:12.941Z', '2023-06-01T07:13:13.613Z', '2023-06-01T07:13:13.813Z', '2023-06-01T07:13:14.917Z', '2023-06-01T07:13:15.029Z', '2023-06-01T07:13:15.373Z', '2023-06-01T07:13:15.549Z', '2023-06-01T07:13:16.141Z', '2023-06-01T07:13:16.357Z', '2023-06-01T07:13:16.661Z', '2023-06-01T07:13:16.869Z', '2023-06-01T07:13:19.245Z', '2023-06-01T07:13:19.373Z', '2023-06-01T07:13:19.581Z', '2023-06-01T07:13:19.797Z', '2023-06-01T07:13:20.005Z', '2023-06-01T07:13:32.317Z', '2023-06-01T07:13:34.637Z', '2023-06-01T07:13:35.180Z', '2023-06-01T07:13:35.340Z', '2023-06-01T07:13:35.461Z', '2023-06-01T07:13:35.669Z', '2023-06-01T07:13:35.813Z', '2023-06-01T07:13:35.965Z', '2023-06-01T07:13:36.749Z', '2023-06-01T07:13:36.997Z', '2023-06-01T07:13:37.237Z', '2023-06-01T07:13:37.373Z', '2023-06-01T07:13:37.750Z', '2023-06-01T07:13:37.901Z', '2023-06-01T07:13:38.004Z', '2023-06-01T07:13:38.125Z', '2023-06-01T07:13:38.260Z', '2023-06-01T07:13:38.461Z', '2023-06-01T07:13:39.253Z', '2023-06-01T07:13:39.420Z', '2023-06-01T07:13:39.589Z', '2023-06-01T07:13:39.764Z', '2023-06-01T07:13:40.140Z', '2023-06-01T07:13:43.853Z', '2023-06-01T07:13:44.805Z', '2023-06-01T07:13:46.356Z', '2023-06-01T07:13:47.653Z', '2023-06-01T07:13:48.153Z', '2023-06-01T07:13:48.183Z', '2023-06-01T07:13:48.205Z', '2023-06-01T07:13:49.636Z', '2023-06-01T07:13:50.143Z', '2023-06-01T07:13:50.172Z', '2023-06-01T07:13:50.203Z', '2023-06-01T07:13:50.242Z', '2023-06-01T07:13:50.272Z', '2023-06-01T07:13:50.302Z', '2023-06-01T07:13:50.333Z', '2023-06-01T07:13:50.373Z', '2023-06-01T07:13:50.403Z', '2023-06-01T07:13:50.433Z', '2023-06-01T07:13:50.472Z', '2023-06-01T07:13:50.502Z', '2023-06-01T07:13:50.533Z', '2023-06-01T07:13:50.562Z', '2023-06-01T07:13:50.602Z', '2023-06-01T07:13:50.632Z', '2023-06-01T07:13:50.663Z', '2023-06-01T07:13:50.703Z', '2023-06-01T07:13:50.732Z', '2023-06-01T07:13:50.762Z', '2023-06-01T07:13:50.802Z', '2023-06-01T07:13:50.832Z', '2023-06-01T07:13:50.862Z', '2023-06-01T07:13:50.903Z', '2023-06-01T07:13:50.932Z', '2023-06-01T07:13:50.965Z', '2023-06-01T07:13:51.003Z', '2023-06-01T07:13:51.033Z', '2023-06-01T07:13:51.063Z', '2023-06-01T07:13:51.094Z', '2023-06-01T07:13:51.133Z', '2023-06-01T07:13:51.162Z', '2023-06-01T07:13:51.192Z', '2023-06-01T07:13:51.222Z', '2023-06-01T07:13:51.263Z', '2023-06-01T07:13:51.303Z', '2023-06-01T07:13:51.323Z', '2023-06-01T07:13:51.363Z', '2023-06-01T07:13:51.392Z', '2023-06-01T07:13:51.422Z', '2023-06-01T07:13:54.220Z', '2023-06-01T07:13:54.604Z', '2023-06-01T07:13:54.780Z', '2023-06-01T07:13:54.957Z', '2023-06-01T07:13:55.164Z', '2023-06-01T07:13:55.428Z', '2023-06-01T07:13:55.588Z', '2023-06-01T07:13:55.828Z', '2023-06-01T07:13:55.964Z', '2023-06-01T07:13:56.204Z', '2023-06-01T07:13:58.133Z', '2023-06-01T07:13:58.316Z', '2023-06-01T07:13:58.532Z', '2023-06-01T07:13:58.724Z', '2023-06-01T07:13:58.876Z', '2023-06-01T07:13:59.188Z', '2023-06-01T07:13:59.300Z', '2023-06-01T07:13:59.444Z', '2023-06-01T07:13:59.652Z', '2023-06-01T07:13:59.836Z', '2023-06-01T07:14:01.020Z', '2023-06-01T07:14:01.196Z', '2023-06-01T07:14:01.372Z', '2023-06-01T07:14:01.540Z', '2023-06-01T07:14:01.796Z', '2023-06-01T07:14:01.940Z', '2023-06-01T07:14:02.236Z', '2023-06-01T07:14:02.516Z', '2023-06-01T07:14:02.676Z', '2023-06-01T07:14:02.916Z', '2023-06-01T07:14:03.092Z', '2023-06-01T07:14:03.340Z', '2023-06-01T07:14:03.548Z', '2023-06-01T07:14:03.732Z', '2023-06-01T07:14:03.916Z', '2023-06-01T07:14:04.164Z', '2023-06-01T07:14:04.284Z', '2023-06-01T07:14:04.428Z', '2023-06-01T07:14:04.676Z', '2023-06-01T07:14:04.772Z', '2023-06-01T07:14:05.588Z', '2023-06-01T07:14:05.748Z', '2023-06-01T07:14:09.142Z', '2023-06-01T07:14:09.396Z', '2023-06-01T07:14:09.908Z', '2023-06-01T07:14:10.004Z', '2023-06-01T07:14:10.268Z', '2023-06-01T07:14:10.428Z', '2023-06-01T07:14:10.628Z', '2023-06-01T07:14:10.845Z', '2023-06-01T07:14:11.493Z', '2023-06-01T07:14:11.645Z', '2023-06-01T07:14:11.949Z', '2023-06-01T07:14:12.301Z', '2023-06-01T07:14:12.477Z', '2023-06-01T07:14:12.965Z', '2023-06-01T07:14:13.117Z', '2023-06-01T07:14:13.261Z', '2023-06-01T07:14:13.477Z', '2023-06-01T07:14:13.661Z', '2023-06-01T07:14:13.821Z', '2023-06-01T07:14:14.143Z', '2023-06-01T07:14:14.269Z', '2023-06-01T07:14:14.429Z', '2023-06-01T07:14:14.573Z', '2023-06-01T07:14:14.717Z', '2023-06-01T07:14:14.885Z', '2023-06-01T07:14:15.101Z', '2023-06-01T07:14:15.285Z', '2023-06-01T07:14:15.445Z', '2023-06-01T07:14:15.597Z', '2023-06-01T07:14:15.821Z', '2023-06-01T07:15:27.974Z', '2023-06-01T07:15:28.126Z', '2023-06-01T07:15:28.510Z', '2023-06-01T07:15:28.830Z', '2023-06-01T07:15:29.054Z', '2023-06-01T07:15:30.046Z', '2023-06-01T07:15:30.254Z', '2023-06-01T07:15:30.422Z', '2023-06-01T07:15:30.926Z', '2023-06-01T07:15:31.206Z', '2023-06-01T07:15:31.366Z', '2023-06-01T07:15:31.574Z', '2023-06-01T07:15:31.718Z', '2023-06-01T07:15:32.334Z', '2023-06-01T07:15:32.558Z', '2023-06-01T07:15:32.758Z', '2023-06-01T07:15:32.950Z', '2023-06-01T07:15:33.414Z', '2023-06-01T07:15:33.670Z', '2023-06-01T07:15:33.934Z', '2023-06-01T07:15:34.102Z', '2023-06-01T07:15:35.166Z', '2023-06-01T07:15:35.430Z', '2023-06-01T07:15:35.566Z', '2023-06-01T07:15:36.342Z', '2023-06-01T07:15:36.542Z', '2023-06-01T07:15:36.918Z', '2023-06-01T07:15:37.101Z', '2023-06-01T07:15:37.326Z', '2023-06-01T07:15:37.518Z', '2023-06-01T07:15:37.662Z', '2023-06-01T07:15:37.959Z', '2023-06-01T07:15:38.110Z', '2023-06-01T07:15:38.302Z', '2023-06-01T07:15:38.486Z', '2023-06-01T07:15:38.654Z', '2023-06-01T07:15:39.150Z', '2023-06-01T07:15:39.270Z', '2023-06-01T07:15:39.454Z', '2023-06-01T07:15:39.598Z', '2023-06-01T07:15:39.750Z', '2023-06-01T07:15:39.942Z', '2023-06-01T07:15:40.134Z', '2023-06-01T07:15:40.366Z', '2023-06-01T07:15:40.630Z', '2023-06-01T07:15:41.462Z', '2023-06-01T07:15:41.590Z', '2023-06-01T07:15:41.718Z', '2023-06-01T07:15:41.862Z', '2023-06-01T07:15:41.926Z', '2023-06-01T07:15:42.118Z', '2023-06-01T07:15:47.342Z', '2023-06-01T07:15:47.502Z', '2023-06-01T07:15:47.687Z', '2023-06-01T07:15:47.854Z', '2023-06-01T07:15:48.110Z', '2023-06-01T07:15:48.238Z', '2023-06-01T07:15:48.422Z', '2023-06-01T07:15:48.566Z', '2023-06-01T07:15:48.719Z', '2023-06-01T07:15:48.910Z', '2023-06-01T07:15:49.142Z', '2023-06-01T07:15:52.886Z', '2023-06-01T07:15:54.838Z', '2023-06-01T07:15:56.062Z', '2023-06-01T07:15:58.198Z', '2023-06-01T07:15:58.445Z', '2023-06-01T07:15:58.893Z', '2023-06-01T07:15:59.037Z', '2023-06-01T07:15:59.214Z', '2023-06-01T07:15:59.397Z', '2023-06-01T07:15:59.589Z', '2023-06-01T07:16:00.069Z', '2023-06-01T07:16:00.677Z', '2023-06-01T07:16:00.909Z', '2023-06-01T07:16:01.286Z', '2023-06-01T07:16:01.662Z', '2023-06-01T07:16:02.190Z', '2023-06-01T07:16:02.494Z', '2023-06-01T07:16:02.606Z', '2023-06-01T07:16:02.765Z', '2023-06-01T07:16:03.014Z', '2023-06-01T07:16:03.214Z', '2023-06-01T07:16:05.485Z', '2023-06-01T07:16:05.581Z', '2023-06-01T07:16:06.061Z', '2023-06-01T07:16:06.302Z', '2023-06-01T07:16:06.509Z', '2023-06-01T07:16:06.613Z', '2023-06-01T07:16:06.813Z', '2023-06-01T07:16:08.462Z', '2023-06-01T07:16:08.861Z', '2023-06-01T07:16:09.646Z', '2023-06-01T07:16:10.013Z', '2023-06-01T07:16:10.141Z', '2023-06-01T07:16:10.365Z', '2023-06-01T07:16:10.749Z', '2023-06-01T07:16:10.917Z', '2023-06-01T07:16:11.277Z', '2023-06-01T07:16:11.414Z', '2023-06-01T07:16:11.573Z', '2023-06-01T07:16:11.789Z', '2023-06-01T07:16:24.767Z', '2023-06-01T07:16:24.999Z', '2023-06-01T07:16:25.151Z', '2023-06-01T07:16:26.335Z', '2023-06-01T07:16:26.503Z', '2023-06-01T07:16:27.175Z', '2023-06-01T07:16:27.319Z', '2023-06-01T07:16:27.559Z', '2023-06-01T07:16:27.711Z', '2023-06-01T07:16:27.935Z', '2023-06-01T07:16:28.175Z', '2023-06-01T07:16:29.599Z', '2023-06-01T07:16:29.775Z', '2023-06-01T07:16:30.007Z', '2023-06-01T07:16:30.279Z', '2023-06-01T07:16:30.479Z', '2023-06-01T07:16:30.591Z', '2023-06-01T07:16:30.863Z', '2023-06-01T07:16:31.087Z', '2023-06-01T07:16:31.311Z', '2023-06-01T07:16:31.519Z', '2023-06-01T07:16:31.855Z', '2023-06-01T07:16:32.103Z', '2023-06-01T07:16:32.287Z', '2023-06-01T07:16:32.407Z', '2023-06-01T07:16:32.695Z', '2023-06-01T07:16:32.871Z', '2023-06-01T07:16:34.215Z', '2023-06-01T07:16:34.655Z', '2023-06-01T07:16:34.822Z', '2023-06-01T07:16:35.015Z', '2023-06-01T07:16:35.759Z', '2023-06-01T07:16:35.887Z', '2023-06-01T07:16:36.143Z', '2023-06-01T07:16:36.375Z', '2023-06-01T07:16:36.567Z', '2023-06-01T07:16:37.007Z', '2023-06-01T07:16:37.159Z', '2023-06-01T07:16:37.407Z', '2023-06-01T07:16:37.671Z', '2023-06-01T07:16:37.847Z', '2023-06-01T07:16:38.023Z', '2023-06-01T07:16:38.110Z', '2023-06-01T07:16:38.270Z', '2023-06-01T07:16:38.535Z', '2023-06-01T07:16:38.775Z', '2023-06-01T07:16:38.903Z', '2023-06-01T07:16:39.119Z', '2023-06-01T07:16:39.391Z', '2023-06-01T07:16:39.518Z', '2023-06-01T07:16:39.631Z', '2023-06-01T07:16:39.783Z', '2023-06-01T07:16:39.975Z', '2023-06-01T07:16:40.279Z', '2023-06-01T07:16:40.543Z', '2023-06-01T07:16:40.679Z', '2023-06-01T07:16:40.831Z', '2023-06-01T07:16:40.959Z', '2023-06-01T07:16:41.167Z', '2023-06-01T07:16:41.262Z', '2023-06-01T07:16:41.471Z', '2023-06-01T07:16:41.590Z', '2023-06-01T07:16:41.839Z', '2023-06-01T07:16:41.927Z', '2023-06-01T07:16:42.110Z', '2023-06-01T07:16:43.263Z', '2023-06-01T07:16:43.399Z', '2023-06-01T07:16:43.631Z', '2023-06-01T07:16:43.799Z', '2023-06-01T07:16:44.022Z', '2023-06-01T07:16:44.215Z', '2023-06-01T07:16:44.959Z', '2023-06-01T07:16:45.078Z', '2023-06-01T07:16:45.279Z', '2023-06-01T07:16:45.439Z', '2023-06-01T07:16:45.984Z', '2023-06-01T07:16:46.143Z', '2023-06-01T07:16:46.327Z', '2023-06-01T07:16:46.591Z', '2023-06-01T07:16:46.854Z', '2023-06-01T07:16:47.055Z', '2023-06-01T07:16:47.175Z']",it was a diet plan for a good health and a trial form spain there is a cadiovasular disease at entrollment so that they maintain a diet plan reduce dietary fat it mixed a olive oil and mixed nuts so that it was a good health for a day of life ,False,real
3KTCJ4SCVGMZHB2B6HCWA7LU59R1M1,"Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events.

In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.

A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.

Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.
",copy paste copy paste copy paste copy paste,"[None, None, None, None, None, None, None, None, '2023-06-01T09:06:36.481Z']","In a multicenter trial in Spain, we randomly assigned participants who were at high cardiovascular risk, but with no cardiovascular disease at enrollment, to one of three diets; a Mediterranean diet supplemented with extra-virgin olive oil, a Mediterranean diet supplemented with mixed nuts, or a control diet (advice to reduce dietary fat). Participants received quarterly individual and group educational sessions and, depending on group assignment, free provision of extra-virgin olive oil, mixed nuts, or small nonfood gifts. The primary end point was the rate of major cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes). On the basis of the results of an interim analysis, the trial was stopped after a median follow-up of 4.8 years.A total of 7447 persons were enrolled (age range, 55 to 80 years); 57% were women. The two Mediterranean-diet groups had good adherence to the intervention, according to self-reported intake and biomarker analyses. A primary end-point event occurred in 288 participants. The multivariable-adjusted hazard ratios were 0.70 (95% confidence interval (CI), 0.54 to 0.92) and 0.72 (95% CI, 0.54 to 0.96) for the group assigned to a Mediterranean diet with extra-virgin olive oil (96 events) and the group assigned to a Mediterranean diet with nuts (83 events), respectively, versus the control group (109 events). No diet-related adverse effects were reported.Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

Observational cohort studies and a secondary prevention trial have shown an inverse association between adherence to the Mediterranean diet and cardiovascular risk. We conducted a randomized trial of this diet pattern for the primary prevention of cardiovascular events. Among persons at high cardiovascular risk, a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced the incidence of major cardiovascular events.",True,real
3UY4PIS8QR65ZTNBIIRWNMAUAZ11N1,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P (0.001) or matched controls (P = 0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Protection against pertussis waned during the 5 years after the fifth dose of DTaP.
",Shift I n Shift U S A c h e n Backspace Backspace i l d r e n u n d e r t h e a g 3 e = = Backspace Backspace Backspace Backspace Backspace e o f 7 w i l l w Backspace g e t 5 d o p Backspace s e s o f Control c copy Control v paste . Control c copy Control v paste Backspace Backspace Backspace Backspace Shift T h e r i s k o f p e r t u s i s Backspace Backspace s i s i n c h i l Backspace Backspace Backspace a l i f o r n i a t h e t i m e s i n c e 2 0 0 6 t o 2 0 0 1 1 Backspace Backspace Backspace 1 1 . Shift Shift W e c o n d u c t e d a s u Backspace Backspace a Backspace c a s e s t u d y w o Backspace h o a l l v a c c i n a t e d w i t h Control c copy Control v paste Shift D a n d Control c copy Control v paste Control c copy . Control v paste,"['2023-06-01T07:21:27.442Z', '2023-06-01T07:21:28.033Z', '2023-06-01T07:21:28.385Z', '2023-06-01T07:21:28.594Z', '2023-06-01T07:21:29.012Z', '2023-06-01T07:21:29.359Z', '2023-06-01T07:21:30.596Z', '2023-06-01T07:21:30.828Z', '2023-06-01T07:21:31.219Z', '2023-06-01T07:21:32.328Z', '2023-06-01T07:21:32.428Z', '2023-06-01T07:21:32.540Z', '2023-06-01T07:21:32.725Z', '2023-06-01T07:21:33.491Z', '2023-06-01T07:21:33.723Z', '2023-06-01T07:21:34.406Z', '2023-06-01T07:21:34.586Z', '2023-06-01T07:21:34.818Z', '2023-06-01T07:21:35.157Z', '2023-06-01T07:21:36.053Z', '2023-06-01T07:21:36.190Z', '2023-06-01T07:21:36.369Z', '2023-06-01T07:21:36.695Z', '2023-06-01T07:21:36.917Z', '2023-06-01T07:21:37.035Z', '2023-06-01T07:21:37.240Z', '2023-06-01T07:21:37.395Z', '2023-06-01T07:21:37.811Z', '2023-06-01T07:21:37.986Z', '2023-06-01T07:21:38.020Z', '2023-06-01T07:21:38.178Z', '2023-06-01T07:21:38.247Z', '2023-06-01T07:21:38.442Z', '2023-06-01T07:21:38.629Z', '2023-06-01T07:21:38.972Z', '2023-06-01T07:21:38.975Z', '2023-06-01T07:21:39.269Z', '2023-06-01T07:21:39.990Z', '2023-06-01T07:21:40.201Z', '2023-06-01T07:21:40.942Z', '2023-06-01T07:21:41.096Z', '2023-06-01T07:21:41.247Z', '2023-06-01T07:21:41.414Z', '2023-06-01T07:21:42.114Z', '2023-06-01T07:21:42.584Z', '2023-06-01T07:21:43.255Z', '2023-06-01T07:21:43.615Z', '2023-06-01T07:21:43.766Z', '2023-06-01T07:21:43.996Z', '2023-06-01T07:21:44.831Z', '2023-06-01T07:21:45.068Z', '2023-06-01T07:21:45.600Z', '2023-06-01T07:21:45.709Z', '2023-06-01T07:21:45.915Z', '2023-06-01T07:21:46.084Z', '2023-06-01T07:21:46.206Z', '2023-06-01T07:21:47.165Z', '2023-06-01T07:21:48.054Z', '2023-06-01T07:21:48.315Z', '2023-06-01T07:21:48.481Z', '2023-06-01T07:21:48.686Z', '2023-06-01T07:21:48.880Z', '2023-06-01T07:21:50.897Z', '2023-06-01T07:21:51.096Z', '2023-06-01T07:21:51.391Z', '2023-06-01T07:21:51.553Z', '2023-06-01T07:21:51.825Z', '2023-06-01T07:21:52.220Z', '2023-06-01T07:21:52.881Z', '2023-06-01T07:21:53.027Z', '2023-06-01T07:21:53.282Z', '2023-06-01T07:21:53.505Z', '2023-06-01T07:21:54.466Z', '2023-06-01T07:21:54.638Z', '2023-06-01T07:21:54.928Z', '2023-06-01T07:22:06.723Z', '2023-06-01T07:22:07.417Z', None, '2023-06-01T07:22:10.000Z', '2023-06-01T07:22:10.388Z', '2023-06-01T07:22:10.588Z', None, '2023-06-01T07:22:22.831Z', '2023-06-01T07:22:23.095Z', '2023-06-01T07:22:30.696Z', '2023-06-01T07:22:31.054Z', None, '2023-06-01T07:22:33.567Z', '2023-06-01T07:22:33.819Z', None, '2023-06-01T07:22:41.768Z', '2023-06-01T07:22:42.677Z', '2023-06-01T07:22:45.526Z', '2023-06-01T07:22:46.350Z', '2023-06-01T07:23:07.636Z', '2023-06-01T07:23:07.864Z', '2023-06-01T07:23:08.149Z', '2023-06-01T07:23:08.288Z', '2023-06-01T07:23:08.535Z', '2023-06-01T07:23:08.988Z', '2023-06-01T07:23:09.226Z', '2023-06-01T07:23:09.426Z', '2023-06-01T07:23:10.382Z', '2023-06-01T07:23:10.593Z', '2023-06-01T07:23:11.121Z', '2023-06-01T07:23:11.299Z', '2023-06-01T07:23:11.487Z', '2023-06-01T07:23:12.235Z', '2023-06-01T07:23:12.416Z', '2023-06-01T07:23:12.493Z', '2023-06-01T07:23:12.918Z', '2023-06-01T07:23:13.095Z', '2023-06-01T07:23:13.299Z', '2023-06-01T07:23:13.533Z', '2023-06-01T07:23:13.707Z', '2023-06-01T07:23:14.635Z', '2023-06-01T07:23:15.168Z', '2023-06-01T07:23:15.585Z', '2023-06-01T07:23:16.678Z', '2023-06-01T07:23:16.950Z', '2023-06-01T07:23:17.955Z', '2023-06-01T07:23:18.352Z', '2023-06-01T07:23:18.501Z', '2023-06-01T07:23:18.661Z', '2023-06-01T07:23:21.669Z', '2023-06-01T07:23:21.907Z', '2023-06-01T07:23:22.751Z', '2023-06-01T07:23:22.956Z', '2023-06-01T07:23:23.379Z', '2023-06-01T07:23:23.587Z', '2023-06-01T07:23:23.778Z', '2023-06-01T07:23:25.098Z', '2023-06-01T07:23:25.265Z', '2023-06-01T07:23:25.482Z', '2023-06-01T07:23:25.907Z', '2023-06-01T07:23:26.488Z', '2023-06-01T07:23:26.736Z', '2023-06-01T07:23:27.287Z', '2023-06-01T07:23:27.505Z', '2023-06-01T07:23:28.193Z', '2023-06-01T07:23:28.392Z', '2023-06-01T07:23:44.260Z', '2023-06-01T07:23:44.371Z', '2023-06-01T07:23:44.501Z', '2023-06-01T07:23:44.592Z', '2023-06-01T07:23:44.804Z', '2023-06-01T07:23:44.987Z', '2023-06-01T07:23:45.212Z', '2023-06-01T07:23:45.352Z', '2023-06-01T07:23:45.499Z', '2023-06-01T07:23:45.792Z', '2023-06-01T07:23:45.950Z', '2023-06-01T07:23:46.114Z', '2023-06-01T07:23:46.381Z', '2023-06-01T07:23:46.455Z', '2023-06-01T07:23:46.824Z', '2023-06-01T07:23:49.775Z', '2023-06-01T07:23:50.030Z', '2023-06-01T07:23:50.181Z', '2023-06-01T07:23:50.492Z', '2023-06-01T07:23:50.824Z', '2023-06-01T07:23:51.263Z', '2023-06-01T07:23:51.389Z', '2023-06-01T07:23:51.597Z', '2023-06-01T07:23:52.284Z', '2023-06-01T07:23:52.511Z', '2023-06-01T07:23:52.654Z', '2023-06-01T07:23:52.876Z', '2023-06-01T07:23:53.046Z', '2023-06-01T07:23:54.130Z', '2023-06-01T07:23:54.297Z', '2023-06-01T07:23:54.455Z', '2023-06-01T07:23:55.452Z', '2023-06-01T07:23:55.594Z', '2023-06-01T07:23:56.602Z', '2023-06-01T07:23:56.963Z', '2023-06-01T07:24:03.644Z', '2023-06-01T07:24:05.673Z', '2023-06-01T07:24:05.864Z', '2023-06-01T07:24:06.145Z', '2023-06-01T07:24:06.530Z', '2023-06-01T07:24:07.800Z', '2023-06-01T07:24:07.966Z', '2023-06-01T07:24:08.135Z', '2023-06-01T07:24:08.415Z', '2023-06-01T07:24:08.654Z', '2023-06-01T07:24:08.849Z', '2023-06-01T07:24:09.125Z', '2023-06-01T07:24:09.307Z', '2023-06-01T07:24:09.571Z', '2023-06-01T07:24:09.708Z', '2023-06-01T07:24:10.048Z', '2023-06-01T07:24:10.226Z', '2023-06-01T07:24:10.428Z', '2023-06-01T07:24:10.655Z', '2023-06-01T07:24:12.115Z', '2023-06-01T07:24:12.321Z', '2023-06-01T07:24:12.794Z', '2023-06-01T07:24:13.329Z', '2023-06-01T07:24:13.629Z', '2023-06-01T07:24:13.751Z', '2023-06-01T07:24:13.900Z', '2023-06-01T07:24:14.048Z', '2023-06-01T07:24:14.275Z', '2023-06-01T07:24:14.537Z', '2023-06-01T07:24:15.261Z', '2023-06-01T07:24:15.498Z', '2023-06-01T07:24:16.080Z', '2023-06-01T07:24:16.356Z', '2023-06-01T07:24:16.594Z', '2023-06-01T07:24:25.122Z', '2023-06-01T07:24:25.882Z', '2023-06-01T07:24:26.456Z', '2023-06-01T07:24:27.209Z', '2023-06-01T07:24:27.367Z', '2023-06-01T07:24:27.594Z', '2023-06-01T07:24:27.998Z', '2023-06-01T07:24:28.151Z', '2023-06-01T07:24:28.304Z', '2023-06-01T07:24:28.494Z', '2023-06-01T07:24:29.145Z', '2023-06-01T07:24:29.288Z', '2023-06-01T07:24:29.502Z', '2023-06-01T07:24:29.714Z', '2023-06-01T07:24:29.980Z', '2023-06-01T07:24:30.203Z', '2023-06-01T07:24:30.331Z', '2023-06-01T07:24:30.480Z', '2023-06-01T07:24:30.647Z', '2023-06-01T07:24:30.839Z', '2023-06-01T07:24:31.037Z', '2023-06-01T07:24:33.997Z', '2023-06-01T07:24:34.236Z', '2023-06-01T07:24:34.360Z', '2023-06-01T07:24:34.497Z', '2023-06-01T07:24:34.709Z', '2023-06-01T07:24:41.622Z', '2023-06-01T07:24:42.026Z', None, '2023-06-01T07:24:44.869Z', '2023-06-01T07:24:45.025Z', None, '2023-06-01T07:24:47.328Z', '2023-06-01T07:24:47.647Z', '2023-06-01T07:24:55.892Z', '2023-06-01T07:24:57.082Z', '2023-06-01T07:24:57.216Z', '2023-06-01T07:24:57.383Z', '2023-06-01T07:24:57.536Z', '2023-06-01T07:25:16.532Z', '2023-06-01T07:25:16.808Z', None, '2023-06-01T07:25:19.037Z', '2023-06-01T07:25:19.292Z', None, '2023-06-01T07:25:32.536Z', '2023-06-01T07:25:33.283Z', None, '2023-06-01T07:25:37.809Z', '2023-06-01T07:25:38.038Z', '2023-06-01T07:25:38.274Z', '2023-06-01T07:25:38.456Z', None]","In USA children under the age of 7 will get 5 doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine.The duration of protection of DTaP is unknown.The risk of pertussis in california the time since 2006 to 2011. We conducted a case study who all vaccinated with DTaP at 47 to 84 months of age and compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) . We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose",True,real
3UY4PIS8QR65ZTNBIIRWNMAUAZ11N1,"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children

In the United States, children receive five doses of diphtheria, tetanus, and acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five doses of DTaP is unknown.

We assessed the risk of pertussis in children in California relative to the time since the fifth dose of DTaP from 2006 to 2011. This period included a large outbreak in 2010. We conducted a case - control study involving members of Kaiser Permanente Northern California who were vaccinated with DTaP at 47 to 84 months of age. We compared children with pertussis confirmed by a positive polymerase-chain-reaction (PCR) assay with two sets of controls; those who were PCR-negative for pertussis and closely matched controls from the general population of health-plan members. We used logistic regression to examine the risk of pertussis in relation to the duration of time since the fifth DTaP dose. Children who received whole-cell pertussis vaccine during infancy or who received any pertussis-containing vaccine after their fifth dose of DTaP were excluded.

We compared 277 children, 4 to 12 years of age, who were PCR-positive for pertussis with 3318 PCR-negative controls and 6086 matched controls. PCR-positive children were more likely to have received the fifth DTaP dose earlier than PCR-negative controls (P (0.001) or matched controls (P = 0.005). Comparison with PCR-negative controls yielded an odds ratio of 1.42 (95% confidence interval, 1.21 to 1.66), indicating that after the fifth dose of DTaP, the odds of acquiring pertussis increased by an average of 42% per year.

Protection against pertussis waned during the 5 years after the fifth dose of DTaP.
",copy copy Shift T h i s i s Shift A n Backspace Backspace Backspace a n e m e r g e n c y a n o Backspace n o u n c e n Backspace m e n t o f t h e c h l Backspace i l d r e n v a c c i n e . Shift W h i c h i d Backspace Backspace Backspace Backspace i s t o t a k e a t t h e a g e o f 4 t o 1 2 . t h i s Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace o Backspace b e t w e e n 4 t o 6 . Shift W h i c h i s v e r y i m p o p o r t a n t f o r t h e c h i l d Backspace g r o w t h i n t h a t s t a g e .,"[None, None, '2023-06-01T08:20:30.835Z', '2023-06-01T08:20:31.197Z', '2023-06-01T08:20:31.519Z', '2023-06-01T08:20:31.797Z', '2023-06-01T08:20:32.497Z', '2023-06-01T08:20:32.720Z', '2023-06-01T08:20:33.149Z', '2023-06-01T08:20:33.673Z', '2023-06-01T08:20:33.959Z', '2023-06-01T08:20:34.890Z', '2023-06-01T08:20:35.019Z', '2023-06-01T08:20:35.439Z', '2023-06-01T08:20:35.656Z', '2023-06-01T08:20:38.060Z', '2023-06-01T08:20:38.392Z', '2023-06-01T08:20:38.641Z', '2023-06-01T08:20:39.737Z', '2023-06-01T08:20:40.461Z', '2023-06-01T08:20:40.705Z', '2023-06-01T08:20:48.696Z', '2023-06-01T08:20:49.102Z', '2023-06-01T08:20:49.594Z', '2023-06-01T08:20:49.729Z', '2023-06-01T08:20:50.024Z', '2023-06-01T08:20:50.262Z', '2023-06-01T08:20:50.752Z', '2023-06-01T08:20:51.088Z', '2023-06-01T08:20:51.470Z', '2023-06-01T08:20:51.788Z', '2023-06-01T08:20:54.462Z', '2023-06-01T08:20:54.933Z', '2023-06-01T08:20:55.318Z', '2023-06-01T08:20:56.316Z', '2023-06-01T08:20:57.348Z', '2023-06-01T08:20:58.269Z', '2023-06-01T08:20:59.013Z', '2023-06-01T08:20:59.354Z', '2023-06-01T08:21:00.049Z', '2023-06-01T08:21:00.295Z', '2023-06-01T08:21:00.704Z', '2023-06-01T08:21:01.504Z', '2023-06-01T08:21:03.219Z', '2023-06-01T08:21:03.647Z', '2023-06-01T08:21:03.969Z', '2023-06-01T08:21:04.213Z', '2023-06-01T08:21:04.551Z', '2023-06-01T08:21:06.803Z', '2023-06-01T08:21:11.326Z', '2023-06-01T08:21:11.612Z', '2023-06-01T08:21:11.970Z', '2023-06-01T08:21:12.070Z', '2023-06-01T08:21:12.672Z', '2023-06-01T08:21:13.054Z', '2023-06-01T08:21:14.163Z', '2023-06-01T08:21:15.086Z', '2023-06-01T08:21:15.520Z', '2023-06-01T08:21:16.765Z', '2023-06-01T08:21:17.754Z', '2023-06-01T08:21:18.043Z', '2023-06-01T08:21:18.450Z', '2023-06-01T08:21:18.703Z', '2023-06-01T08:21:18.902Z', '2023-06-01T08:21:19.564Z', '2023-06-01T08:21:19.887Z', '2023-06-01T08:21:20.951Z', '2023-06-01T08:21:21.276Z', '2023-06-01T08:21:21.636Z', '2023-06-01T08:21:21.815Z', '2023-06-01T08:21:22.135Z', '2023-06-01T08:21:22.376Z', '2023-06-01T08:21:22.654Z', '2023-06-01T08:21:24.215Z', '2023-06-01T08:21:28.160Z', '2023-06-01T08:21:28.469Z', '2023-06-01T08:21:28.873Z', '2023-06-01T08:21:29.311Z', '2023-06-01T08:21:30.653Z', '2023-06-01T08:21:30.984Z', '2023-06-01T08:21:31.283Z', '2023-06-01T08:21:31.591Z', '2023-06-01T08:21:31.920Z', '2023-06-01T08:21:32.145Z', '2023-06-01T08:21:33.607Z', '2023-06-01T08:21:33.820Z', '2023-06-01T08:21:34.068Z', '2023-06-01T08:21:34.270Z', '2023-06-01T08:21:40.321Z', '2023-06-01T08:21:42.028Z', '2023-06-01T08:21:43.631Z', '2023-06-01T08:21:43.938Z', '2023-06-01T08:21:44.215Z', '2023-06-01T08:21:48.841Z', '2023-06-01T08:21:49.220Z', '2023-06-01T08:21:49.389Z', '2023-06-01T08:21:50.253Z', '2023-06-01T08:21:50.831Z', '2023-06-01T08:21:51.184Z', '2023-06-01T08:21:51.582Z', '2023-06-01T08:21:51.778Z', '2023-06-01T08:21:52.777Z', '2023-06-01T08:21:53.196Z', '2023-06-01T08:21:53.500Z', '2023-06-01T08:21:53.981Z', '2023-06-01T08:21:54.131Z', '2023-06-01T08:21:54.692Z', '2023-06-01T08:21:55.035Z', '2023-06-01T08:22:04.612Z', '2023-06-01T08:22:05.769Z', '2023-06-01T08:22:06.149Z', '2023-06-01T08:22:07.504Z', '2023-06-01T08:22:09.506Z', '2023-06-01T08:22:10.321Z', '2023-06-01T08:22:11.091Z', '2023-06-01T08:22:13.081Z', '2023-06-01T08:22:13.465Z', '2023-06-01T08:22:13.957Z', '2023-06-01T08:22:14.524Z', '2023-06-01T08:22:14.880Z', '2023-06-01T08:22:16.238Z', '2023-06-01T08:22:16.364Z', '2023-06-01T08:22:18.668Z', '2023-06-01T08:22:23.778Z', '2023-06-01T08:22:24.182Z', '2023-06-01T08:22:24.314Z', '2023-06-01T08:22:24.545Z', '2023-06-01T08:22:25.183Z', '2023-06-01T08:22:26.264Z', '2023-06-01T08:22:26.763Z', '2023-06-01T08:22:26.801Z', '2023-06-01T08:22:26.842Z', '2023-06-01T08:22:26.873Z', '2023-06-01T08:22:26.903Z', '2023-06-01T08:22:26.942Z', '2023-06-01T08:22:26.971Z', '2023-06-01T08:22:27.035Z', '2023-06-01T08:22:27.060Z', '2023-06-01T08:22:27.073Z', '2023-06-01T08:22:27.092Z', '2023-06-01T08:22:27.130Z', '2023-06-01T08:22:27.161Z', '2023-06-01T08:22:27.202Z', '2023-06-01T08:22:27.233Z', '2023-06-01T08:22:27.262Z', '2023-06-01T08:22:29.141Z', '2023-06-01T08:22:30.635Z', '2023-06-01T08:22:31.652Z', '2023-06-01T08:22:32.430Z', '2023-06-01T08:22:32.862Z', '2023-06-01T08:22:33.422Z', '2023-06-01T08:22:34.034Z', '2023-06-01T08:22:34.289Z', '2023-06-01T08:22:34.457Z', '2023-06-01T08:22:34.897Z', '2023-06-01T08:22:35.253Z', '2023-06-01T08:22:37.649Z', '2023-06-01T08:22:38.222Z', '2023-06-01T08:22:38.477Z', '2023-06-01T08:22:38.760Z', '2023-06-01T08:22:39.115Z', '2023-06-01T08:22:39.618Z', '2023-06-01T08:22:40.266Z', '2023-06-01T08:22:51.193Z', '2023-06-01T08:22:51.618Z', '2023-06-01T08:22:52.060Z', '2023-06-01T08:22:52.346Z', '2023-06-01T08:22:52.908Z', '2023-06-01T08:22:53.211Z', '2023-06-01T08:22:53.486Z', '2023-06-01T08:22:54.443Z', '2023-06-01T08:22:54.900Z', '2023-06-01T08:22:55.219Z', '2023-06-01T08:22:55.467Z', '2023-06-01T08:22:55.807Z', '2023-06-01T08:22:55.900Z', '2023-06-01T08:22:56.219Z', '2023-06-01T08:22:56.530Z', '2023-06-01T08:22:57.071Z', '2023-06-01T08:22:57.346Z', '2023-06-01T08:22:57.682Z', '2023-06-01T08:22:57.704Z', '2023-06-01T08:22:57.878Z', '2023-06-01T08:22:57.891Z', '2023-06-01T08:22:58.483Z', '2023-06-01T08:22:58.821Z', '2023-06-01T08:22:59.284Z', '2023-06-01T08:22:59.650Z', '2023-06-01T08:22:59.890Z', '2023-06-01T08:23:00.199Z', '2023-06-01T08:23:00.478Z', '2023-06-01T08:23:00.776Z', '2023-06-01T08:23:01.398Z', '2023-06-01T08:23:01.628Z', '2023-06-01T08:23:01.918Z', '2023-06-01T08:23:02.031Z', '2023-06-01T08:23:02.350Z', '2023-06-01T08:23:02.681Z', '2023-06-01T08:23:11.596Z', '2023-06-01T08:23:12.045Z', '2023-06-01T08:23:12.513Z', '2023-06-01T08:23:12.813Z', '2023-06-01T08:23:13.351Z', '2023-06-01T08:23:13.997Z', '2023-06-01T08:23:16.277Z', '2023-06-01T08:23:17.490Z', '2023-06-01T08:23:18.577Z', '2023-06-01T08:23:19.340Z', '2023-06-01T08:23:19.607Z', '2023-06-01T08:23:20.624Z', '2023-06-01T08:23:20.914Z', '2023-06-01T08:23:21.171Z', '2023-06-01T08:23:21.392Z', '2023-06-01T08:23:21.745Z', '2023-06-01T08:23:22.024Z', '2023-06-01T08:23:22.225Z', '2023-06-01T08:23:22.630Z', '2023-06-01T08:23:22.746Z', '2023-06-01T08:23:23.227Z', '2023-06-01T08:23:23.560Z', '2023-06-01T08:23:23.848Z', '2023-06-01T08:23:24.118Z', '2023-06-01T08:23:24.418Z', '2023-06-01T08:23:24.931Z', '2023-06-01T08:23:25.585Z', '2023-06-01T08:23:25.793Z', '2023-06-01T08:23:27.898Z']",This is an emergency announcement of the children vaccine. Which is to take at the age between 4 to 6.Which is very important for the child growth in that stage.,False,real
3MZ3TAMYTL81EXB1JWTJO5WQSY0RI6,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",paste,[None],"We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-varianceweighted meta-analysis.",True,real
3MZ3TAMYTL81EXB1JWTJO5WQSY0RI6,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",Control v paste,"['2023-06-01T09:00:53.144Z', '2023-06-01T09:00:53.624Z', None]","Diet and lifestyle factors contribute to development of obesity and overweight. Some of the most common ones are:

eating large amounts of processed or fast food  this is food that's high in fat and sugar
drinking too much alcohol  alcohol contains a lot of calories
eating out a lot  food cooked in a restaurant may be higher in fat and sugar
eating larger portions than you need
drinking too many sugary drinks  including soft drinks and fruit juice
comfort eating  some people may comfort eat due to many other factors affecting their life such as low self-esteem or low mood
Changes in society have also made it more difficult to have a healthy diet. High calorie food has become cheaper and more convenient, and is heavily advertised and promoted.",True,real
3MZ3TAMYTL81EXB1JWTJO5WQSY0RI6,"Changes in Diet and Lifestyle and Long-Term Weight Gain in Women and Men

Specific dietary and other lifestyle behaviors may affect the success of the straightforward-sounding strategy `` eat less and exercise more '' for preventing long-term weight gain.

We performed prospective investigations involving three separate cohorts that included 120,877 U.S. women and men who were free of chronic diseases and not obese at baseline, with follow-up periods from 1986 to 2006, 1991 to 2003, and 1986 to 2006. The relationships between changes in lifestyle factors and weight change were evaluated at 4-year intervals, with multivariable adjustments made for age, baseline body-mass index for each period, and all lifestyle factors simultaneously. Cohort-specific and sex-specific results were similar and were pooled with the use of an inverse-variance - weighted meta-analysis.

Within each 4-year period, participants gained an average of 3.35 lb (5th to 95th percentile,  4.1 to 12.4). On the basis of increased daily servings of individual dietary components, 4-year weight change was most strongly associated with the intake of potato chips (1.69 lb), potatoes (1.28 lb), sugar-sweetened beverages (1.00 lb), unprocessed red meats (0.95 lb), and processed meats (0.93 lb) and was inversely associated with the intake of vegetables ( 0.22 lb), whole grains ( 0.37 lb), fruits ( 0.49 lb), nuts ( 0.57 lb), and yogurt ( 0.82 lb) (P  0.005 for each comparison). Aggregate dietary changes were associated with substantial differences in weight change (3.93 lb across quintiles of dietary change). Other lifestyle factors were also independently associated with weight change (P (0.001), including physical activity ( 1.76 lb across quintiles); alcohol use (0.41 lb per drink per day), smoking (new quitters, 5.17 lb; former smokers, 0.14 lb), sleep (more weight gain with (6 or) 8 hours of sleep), and television watching (0.31 lb per hour per day).

Specific dietary and lifestyle factors are independently associated with long-term weight gain, with a substantial aggregate effect and implications for strategies to prevent obesity.
",copy copy copy copy paste,"[None, None, None, None, None]","This study examined the relationship between diet and lifestyle factors and long-term weight gain in three separate cohorts of 120,877 U.S. women and men. It was found that dietary components such as potato chips, potatoes, sugar-sweetened beverages, unprocessed red meats, and processed meats influenced weight changes during four-year intervals, while increases in daily servings of vegetables, whole grains, fruits, nuts, and yogurt had the opposite effect. Other lifestyle factors including physical activity, alcohol use, smoking, sleep, and television watching were also linked to weight change. It was concluded that specific dietary and different lifestyle factors can have a substantial effect on preventing obesity.",True,synthetic
3B623HUYJ4BKQ6Z1PZHX1Q78B4F8S4,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
",copy paste copy paste,"[None, None, None, None]","We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health.Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders.",True,real
3B623HUYJ4BKQ6Z1PZHX1Q78B4F8S4,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
","h Backspace c d c r e c o m m e n d s t h Backspace Backspace Backspace Backspace Backspace Backspace a t p w Backspace e p o l r Backspace e Backspace Backspace Backspace Backspace Backspace Backspace Backspace p e o p l e g r Backspace e t m m r v a c c i n e t o p r o t e c t a g a i n t s Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace m e a s l e s , m u m p s , a n d r u b e l l a . c h i l d r e n s h o u l d g e t t w o d o e s e s o f m m r v a c c i n e , s t a r t i n g w i t h t h e f i r s t d o e s a s 1 2 t o 1 5 m o n t h s o f a g e , a n d t h e s e c o n d d o e s a t 4 t h r o u g h 6 y e a r s o f a g e . t e e n s a n d a d u l t s s h o u l d a Backspace a l s o b e u p o f a g e , Backspace . t w o m m r v a c c i n e s a r e a v a i l a b l e . Backspace f o r u s e i n t h e u n i t e d s t a t e s , m - m - r 1 1","['2023-06-01T11:58:43.789Z', '2023-06-01T11:58:44.559Z', '2023-06-01T11:59:03.131Z', '2023-06-01T11:59:03.360Z', '2023-06-01T11:59:04.692Z', '2023-06-01T11:59:05.846Z', '2023-06-01T11:59:10.163Z', '2023-06-01T11:59:10.369Z', '2023-06-01T11:59:12.379Z', '2023-06-01T11:59:12.818Z', '2023-06-01T11:59:14.679Z', '2023-06-01T11:59:14.939Z', '2023-06-01T11:59:15.451Z', '2023-06-01T11:59:16.173Z', '2023-06-01T11:59:21.236Z', '2023-06-01T11:59:21.438Z', '2023-06-01T11:59:22.273Z', '2023-06-01T11:59:22.717Z', '2023-06-01T11:59:23.968Z', '2023-06-01T11:59:29.789Z', '2023-06-01T11:59:30.007Z', '2023-06-01T11:59:30.180Z', '2023-06-01T11:59:30.341Z', '2023-06-01T11:59:30.521Z', '2023-06-01T11:59:30.682Z', '2023-06-01T11:59:35.091Z', '2023-06-01T11:59:35.475Z', '2023-06-01T11:59:36.212Z', '2023-06-01T11:59:38.525Z', '2023-06-01T11:59:39.017Z', '2023-06-01T11:59:39.812Z', '2023-06-01T11:59:40.365Z', '2023-06-01T11:59:40.894Z', '2023-06-01T11:59:41.094Z', '2023-06-01T11:59:41.308Z', '2023-06-01T11:59:41.722Z', '2023-06-01T11:59:42.560Z', '2023-06-01T11:59:42.872Z', '2023-06-01T11:59:43.188Z', '2023-06-01T11:59:47.953Z', '2023-06-01T11:59:48.270Z', '2023-06-01T11:59:48.467Z', '2023-06-01T11:59:48.715Z', '2023-06-01T11:59:48.875Z', '2023-06-01T11:59:49.034Z', '2023-06-01T11:59:49.377Z', '2023-06-01T11:59:52.068Z', '2023-06-01T11:59:52.840Z', '2023-06-01T11:59:53.360Z', '2023-06-01T11:59:55.750Z', '2023-06-01T11:59:56.321Z', '2023-06-01T11:59:56.594Z', '2023-06-01T11:59:57.627Z', '2023-06-01T11:59:57.957Z', '2023-06-01T11:59:58.218Z', '2023-06-01T11:59:58.878Z', '2023-06-01T11:59:59.356Z', '2023-06-01T11:59:59.588Z', '2023-06-01T12:00:00.658Z', '2023-06-01T12:00:01.432Z', '2023-06-01T12:00:01.677Z', '2023-06-01T12:00:02.032Z', '2023-06-01T12:00:03.122Z', '2023-06-01T12:00:04.600Z', '2023-06-01T12:00:04.951Z', '2023-06-01T12:00:06.228Z', '2023-06-01T12:00:06.480Z', '2023-06-01T12:00:06.978Z', '2023-06-01T12:00:07.827Z', '2023-06-01T12:00:08.279Z', '2023-06-01T12:00:09.499Z', '2023-06-01T12:00:09.835Z', '2023-06-01T12:00:10.280Z', '2023-06-01T12:00:11.221Z', '2023-06-01T12:00:12.155Z', '2023-06-01T12:00:12.388Z', '2023-06-01T12:00:12.857Z', '2023-06-01T12:00:14.148Z', '2023-06-01T12:00:14.708Z', '2023-06-01T12:00:15.177Z', '2023-06-01T12:00:15.599Z', '2023-06-01T12:00:17.269Z', '2023-06-01T12:00:23.234Z', '2023-06-01T12:00:23.943Z', '2023-06-01T12:00:24.307Z', '2023-06-01T12:00:24.828Z', '2023-06-01T12:00:25.166Z', '2023-06-01T12:00:27.528Z', '2023-06-01T12:00:28.599Z', '2023-06-01T12:00:29.070Z', '2023-06-01T12:00:33.879Z', '2023-06-01T12:00:34.071Z', '2023-06-01T12:00:34.395Z', '2023-06-01T12:00:37.843Z', '2023-06-01T12:00:40.876Z', '2023-06-01T12:00:50.394Z', '2023-06-01T12:00:50.768Z', '2023-06-01T12:00:50.802Z', '2023-06-01T12:00:51.045Z', '2023-06-01T12:00:51.273Z', '2023-06-01T12:00:51.474Z', '2023-06-01T12:00:51.639Z', '2023-06-01T12:00:51.915Z', '2023-06-01T12:00:52.192Z', '2023-06-01T12:00:52.845Z', '2023-06-01T12:00:54.043Z', '2023-06-01T12:00:55.429Z', '2023-06-01T12:00:55.915Z', '2023-06-01T12:00:57.990Z', '2023-06-01T12:01:01.395Z', '2023-06-01T12:01:01.909Z', '2023-06-01T12:01:02.409Z', '2023-06-01T12:01:03.169Z', '2023-06-01T12:01:04.122Z', '2023-06-01T12:01:04.999Z', '2023-06-01T12:01:05.300Z', '2023-06-01T12:01:05.649Z', '2023-06-01T12:01:06.341Z', '2023-06-01T12:01:07.575Z', '2023-06-01T12:01:08.680Z', '2023-06-01T12:01:09.620Z', '2023-06-01T12:01:13.417Z', '2023-06-01T12:01:13.929Z', '2023-06-01T12:01:14.859Z', '2023-06-01T12:01:15.565Z', '2023-06-01T12:01:16.247Z', '2023-06-01T12:01:16.710Z', '2023-06-01T12:01:17.279Z', '2023-06-01T12:01:17.708Z', '2023-06-01T12:01:18.299Z', '2023-06-01T12:01:18.564Z', '2023-06-01T12:01:20.461Z', '2023-06-01T12:01:21.409Z', '2023-06-01T12:01:22.410Z', '2023-06-01T12:01:22.914Z', '2023-06-01T12:01:23.320Z', '2023-06-01T12:01:23.629Z', '2023-06-01T12:01:23.950Z', '2023-06-01T12:01:24.719Z', '2023-06-01T12:01:24.969Z', '2023-06-01T12:01:25.192Z', '2023-06-01T12:01:25.739Z', '2023-06-01T12:01:26.040Z', '2023-06-01T12:01:36.648Z', '2023-06-01T12:01:37.478Z', '2023-06-01T12:01:37.848Z', '2023-06-01T12:01:38.238Z', '2023-06-01T12:01:39.528Z', '2023-06-01T12:01:40.013Z', '2023-06-01T12:01:40.778Z', '2023-06-01T12:01:43.059Z', '2023-06-01T12:01:43.418Z', '2023-06-01T12:01:43.628Z', '2023-06-01T12:01:43.998Z', '2023-06-01T12:01:44.971Z', '2023-06-01T12:01:45.888Z', '2023-06-01T12:01:46.368Z', '2023-06-01T12:01:47.120Z', '2023-06-01T12:01:47.738Z', '2023-06-01T12:01:48.568Z', '2023-06-01T12:01:49.061Z', '2023-06-01T12:01:50.218Z', '2023-06-01T12:01:50.393Z', '2023-06-01T12:01:50.628Z', '2023-06-01T12:01:51.759Z', '2023-06-01T12:01:52.181Z', '2023-06-01T12:01:52.969Z', '2023-06-01T12:01:53.636Z', '2023-06-01T12:01:54.186Z', '2023-06-01T12:01:54.378Z', '2023-06-01T12:01:54.769Z', '2023-06-01T12:01:55.789Z', '2023-06-01T12:01:56.068Z', '2023-06-01T12:01:56.459Z', '2023-06-01T12:01:57.826Z', '2023-06-01T12:01:58.018Z', '2023-06-01T12:01:58.405Z', '2023-06-01T12:01:58.717Z', '2023-06-01T12:01:59.099Z', '2023-06-01T12:02:00.606Z', '2023-06-01T12:02:01.566Z', '2023-06-01T12:02:01.920Z', '2023-06-01T12:02:03.863Z', '2023-06-01T12:02:05.037Z', '2023-06-01T12:02:05.428Z', '2023-06-01T12:02:08.748Z', '2023-06-01T12:02:09.088Z', '2023-06-01T12:02:09.419Z', '2023-06-01T12:02:10.002Z', '2023-06-01T12:02:10.998Z', '2023-06-01T12:02:11.440Z', '2023-06-01T12:02:11.948Z', '2023-06-01T12:02:12.278Z', '2023-06-01T12:02:12.475Z', '2023-06-01T12:02:12.859Z', '2023-06-01T12:02:13.561Z', '2023-06-01T12:02:13.760Z', '2023-06-01T12:02:14.082Z', '2023-06-01T12:02:14.440Z', '2023-06-01T12:02:17.244Z', '2023-06-01T12:02:17.644Z', '2023-06-01T12:02:18.033Z', '2023-06-01T12:02:18.445Z', '2023-06-01T12:02:18.755Z', '2023-06-01T12:02:19.808Z', '2023-06-01T12:02:20.171Z', '2023-06-01T12:02:20.577Z', '2023-06-01T12:02:21.017Z', '2023-06-01T12:02:21.284Z', '2023-06-01T12:02:22.762Z', '2023-06-01T12:02:23.123Z', '2023-06-01T12:02:24.518Z', '2023-06-01T12:02:24.891Z', '2023-06-01T12:02:25.607Z', '2023-06-01T12:02:25.794Z', '2023-06-01T12:02:26.877Z', '2023-06-01T12:02:27.238Z', '2023-06-01T12:02:27.657Z', '2023-06-01T12:02:28.037Z', '2023-06-01T12:02:28.536Z', '2023-06-01T12:02:28.808Z', '2023-06-01T12:02:30.434Z', '2023-06-01T12:02:30.770Z', '2023-06-01T12:02:31.051Z', '2023-06-01T12:02:31.353Z', '2023-06-01T12:02:32.178Z', '2023-06-01T12:02:32.915Z', '2023-06-01T12:02:33.479Z', '2023-06-01T12:02:34.167Z', '2023-06-01T12:02:34.618Z', '2023-06-01T12:02:35.042Z', '2023-06-01T12:02:35.456Z', '2023-06-01T12:02:35.914Z', '2023-06-01T12:02:36.637Z', '2023-06-01T12:02:36.968Z', '2023-06-01T12:02:39.482Z', '2023-06-01T12:02:41.607Z', '2023-06-01T12:02:41.891Z', '2023-06-01T12:02:42.336Z', '2023-06-01T12:02:42.692Z', '2023-06-01T12:02:43.339Z', '2023-06-01T12:02:47.605Z', '2023-06-01T12:02:47.759Z', '2023-06-01T12:02:48.049Z', '2023-06-01T12:02:48.400Z', '2023-06-01T12:02:48.634Z', '2023-06-01T12:02:48.812Z', '2023-06-01T12:02:49.209Z', '2023-06-01T12:02:49.636Z', '2023-06-01T12:02:49.929Z', '2023-06-01T12:02:50.450Z', '2023-06-01T12:02:51.176Z', '2023-06-01T12:02:52.324Z', '2023-06-01T12:02:52.777Z', '2023-06-01T12:02:53.252Z', '2023-06-01T12:02:53.409Z', '2023-06-01T12:02:54.995Z', '2023-06-01T12:02:55.475Z', '2023-06-01T12:02:55.929Z', '2023-06-01T12:02:57.002Z', '2023-06-01T12:02:57.674Z', '2023-06-01T12:02:58.255Z', '2023-06-01T12:02:59.695Z', '2023-06-01T12:03:00.114Z', '2023-06-01T12:03:01.216Z', '2023-06-01T12:03:01.849Z', '2023-06-01T12:03:02.161Z', '2023-06-01T12:03:02.839Z', '2023-06-01T12:03:03.048Z', '2023-06-01T12:03:05.517Z', '2023-06-01T12:03:06.216Z', '2023-06-01T12:03:07.167Z', '2023-06-01T12:03:08.095Z', '2023-06-01T12:03:08.608Z', '2023-06-01T12:03:08.935Z', '2023-06-01T12:03:09.236Z', '2023-06-01T12:03:09.556Z', '2023-06-01T12:03:10.536Z', '2023-06-01T12:03:11.009Z', '2023-06-01T12:03:11.451Z', '2023-06-01T12:03:11.815Z', '2023-06-01T12:03:12.719Z', '2023-06-01T12:03:13.814Z', '2023-06-01T12:03:14.512Z', '2023-06-01T12:03:16.724Z', '2023-06-01T12:03:18.595Z', '2023-06-01T12:03:21.528Z', '2023-06-01T12:03:21.936Z', '2023-06-01T12:03:22.117Z', '2023-06-01T12:03:22.650Z', '2023-06-01T12:03:23.164Z', '2023-06-01T12:03:24.160Z', '2023-06-01T12:03:24.553Z', '2023-06-01T12:03:24.998Z', '2023-06-01T12:03:25.411Z', '2023-06-01T12:03:25.877Z', '2023-06-01T12:03:26.976Z', '2023-06-01T12:03:27.247Z', '2023-06-01T12:03:29.164Z', '2023-06-01T12:03:29.279Z', '2023-06-01T12:03:29.650Z', '2023-06-01T12:03:31.012Z', '2023-06-01T12:03:31.399Z', '2023-06-01T12:03:31.760Z', '2023-06-01T12:03:32.392Z', '2023-06-01T12:03:32.687Z', '2023-06-01T12:03:32.975Z', '2023-06-01T12:03:33.645Z', '2023-06-01T12:03:34.133Z', '2023-06-01T12:03:36.247Z', '2023-06-01T12:03:37.923Z', '2023-06-01T12:03:38.247Z', '2023-06-01T12:03:38.563Z', '2023-06-01T12:03:39.354Z', '2023-06-01T12:03:39.731Z', '2023-06-01T12:03:40.214Z', '2023-06-01T12:03:40.599Z', '2023-06-01T12:03:43.296Z', '2023-06-01T12:03:43.672Z', '2023-06-01T12:03:44.358Z', '2023-06-01T12:03:44.763Z', '2023-06-01T12:03:45.167Z', '2023-06-01T12:03:45.791Z', '2023-06-01T12:03:46.672Z', '2023-06-01T12:03:47.162Z', '2023-06-01T12:03:47.512Z', '2023-06-01T12:03:47.922Z', '2023-06-01T12:03:49.486Z', '2023-06-01T12:03:49.840Z', '2023-06-01T12:03:50.552Z', '2023-06-01T12:03:51.361Z', '2023-06-01T12:03:51.769Z', '2023-06-01T12:03:52.130Z', '2023-06-01T12:04:03.534Z', '2023-06-01T12:04:04.616Z', '2023-06-01T12:04:05.112Z', '2023-06-01T12:04:06.119Z', '2023-06-01T12:04:07.913Z', '2023-06-01T12:04:08.130Z', '2023-06-01T12:04:08.527Z', '2023-06-01T12:04:09.281Z', '2023-06-01T12:04:09.536Z', '2023-06-01T12:04:09.921Z', '2023-06-01T12:04:10.920Z', '2023-06-01T12:04:11.230Z', '2023-06-01T12:04:12.128Z', '2023-06-01T12:04:12.592Z', '2023-06-01T12:04:13.512Z', '2023-06-01T12:04:13.792Z', '2023-06-01T12:04:14.830Z', '2023-06-01T12:04:15.200Z', '2023-06-01T12:04:15.756Z', '2023-06-01T12:04:15.925Z', '2023-06-01T12:04:16.366Z', '2023-06-01T12:04:17.684Z', '2023-06-01T12:04:18.280Z', '2023-06-01T12:04:18.602Z', '2023-06-01T12:04:19.072Z', '2023-06-01T12:04:19.404Z', '2023-06-01T12:04:19.808Z', '2023-06-01T12:04:20.471Z', '2023-06-01T12:04:20.851Z', '2023-06-01T12:04:21.320Z', '2023-06-01T12:04:23.558Z', '2023-06-01T12:04:27.047Z', '2023-06-01T12:04:27.488Z', '2023-06-01T12:04:27.766Z', '2023-06-01T12:04:28.151Z', '2023-06-01T12:04:28.560Z', '2023-06-01T12:04:28.960Z', '2023-06-01T12:04:29.361Z', '2023-06-01T12:04:29.935Z', '2023-06-01T12:04:30.118Z', '2023-06-01T12:04:32.480Z', '2023-06-01T12:04:32.775Z', '2023-06-01T12:04:33.128Z', '2023-06-01T12:04:33.391Z', '2023-06-01T12:04:33.711Z', '2023-06-01T12:04:33.911Z', '2023-06-01T12:04:34.204Z', '2023-06-01T12:04:35.435Z', '2023-06-01T12:04:41.350Z', '2023-06-01T12:04:41.638Z', '2023-06-01T12:04:41.888Z', '2023-06-01T12:04:42.326Z', '2023-06-01T12:04:42.634Z', '2023-06-01T12:04:44.952Z', '2023-06-01T12:04:46.194Z', '2023-06-01T12:04:46.592Z', '2023-06-01T12:04:48.482Z', '2023-06-01T12:04:48.854Z', '2023-06-01T12:04:49.317Z', '2023-06-01T12:04:49.590Z', '2023-06-01T12:04:49.844Z', '2023-06-01T12:04:51.967Z', '2023-06-01T12:04:57.632Z', '2023-06-01T12:04:59.038Z', '2023-06-01T12:04:59.852Z', '2023-06-01T12:05:00.470Z', '2023-06-01T12:05:02.442Z', '2023-06-01T12:05:03.965Z', '2023-06-01T12:05:05.481Z', '2023-06-01T12:05:05.764Z']"," recommends that people get vaccine to protect measles, mumps,and rubella. children should get two doeses of mmr vaccine, starting with the first does as 12 to 15 months of age, and the second does at 4 through 6 years of age. teens and adults should also be up of age. two mmr vaccines are available for use in the united states,m-m-r 11",False,real
3B623HUYJ4BKQ6Z1PZHX1Q78B4F8S4,"A Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism

It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism.

We conducted a retrospective cohort study of all children born in Denmark from January 1991 through December 1998. The cohort was selected on the basis of data from the Danish Civil Registration System, which assigns a unique identification number to every live-born infant and new resident in Denmark. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children 's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. We obtained information on potential confounders from the Danish Medical Birth Registry, the National Hospital Registry, and Statistics Denmark.

Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0 percent) had received the MMR vaccine. We identified 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 (95 percent confidence interval, 0.68 to 1.24), and the relative risk of another autistic-spectrum disorder was 0.83 (95 percent confidence interval, 0.65 to 1.07). There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder.

This study provides strong evidence against the hypothesis that MMR vaccination causes autism.
",Control c copy c copy c copy Control c copy c copy c copy Control v paste,"['2023-06-01T09:25:34.144Z', '2023-06-01T09:25:34.576Z', None, '2023-06-01T09:25:34.799Z', None, '2023-06-01T09:25:34.981Z', None, '2023-06-01T09:25:40.721Z', '2023-06-01T09:25:40.960Z', None, '2023-06-01T09:25:41.151Z', None, '2023-06-01T09:25:41.360Z', None, '2023-06-01T09:27:15.506Z', '2023-06-01T09:27:15.745Z', None]","It has been suggested that vaccination against measles, mumps, and rubella (MMR) is a cause of autism. A retrospective cohort study of all children born in Denmark from January 1991 through December 1998 was conducted. MMR-vaccination status was obtained from the Danish National Board of Health. Information on the children's autism status was obtained from the Danish Psychiatric Central Register, which contains information on all diagnoses received by patients in psychiatric hospitals and outpatient clinics in Denmark. Of the 537,303 children in the cohort (representing 2,129,864 person-years), 440,655 (82.0%) had received the MMR vaccine. 316 children with a diagnosis of autistic disorder and 422 with a diagnosis of other autistic-spectrum disorders were identified. After adjustment for potential confounders, the relative risk of autistic disorder in the group of vaccinated children, as compared with the unvaccinated group, was 0.92 and the relative risk of another autistic-spectrum disorder was 0.83. There was no association between the age at the time of vaccination, the time since vaccination, or the date of vaccination and the development of autistic disorder. ",True,real
371DNNCG44NL56CGEZMNBV3UDNT8TT,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
",copy Control v paste,"[None, '2023-06-01T06:37:40.527Z', '2023-06-01T06:37:40.949Z', None]","This trial evaluated the immunogenicity and safety of an inactivated, split-virus 2009 H1N1 vaccine administered in two doses to healthy adults between the ages of 18 and 64 years. Both a 15 g and 30 g dose were administered intramuscularly, 21 days apart. The coprimary immunogenicity end points included the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer. Results showed the vaccine to be highly immunogenic and mild-to-moderate vaccine-related reactions were observed. No deaths or serious adverse events were reported. Local injection-site discomfort and systemic symptoms such as headache were reported by a majority of participants. These results demonstrate the safety and potential effectiveness of the vaccine to mitigate 2009 H1N1 virus spread.",True,synthetic
371DNNCG44NL56CGEZMNBV3UDNT8TT,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
",Control c copy Control v paste Control c copy Control v paste Control c copy Control v paste,"['2023-06-01T07:30:23.498Z', '2023-06-01T07:30:23.816Z', None, '2023-06-01T07:30:25.366Z', '2023-06-01T07:30:25.604Z', None, '2023-06-01T07:30:42.153Z', '2023-06-01T07:30:42.398Z', None, '2023-06-01T07:30:44.443Z', '2023-06-01T07:30:44.793Z', None, '2023-06-01T07:30:50.308Z', '2023-06-01T07:30:50.628Z', None, '2023-06-01T07:30:57.134Z', '2023-06-01T07:30:57.500Z', '2023-06-01T07:30:57.791Z', None]","A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years.We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions. ",True,real
371DNNCG44NL56CGEZMNBV3UDNT8TT,"Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

A novel 2009 influenza A (H1N1) virus is responsible for the first influenza pandemic in 41 years. A safe and effective vaccine is needed. A randomized, observer-blind, parallel-group trial evaluating two doses of an inactivated, split-virus 2009 H1N1 vaccine in healthy adults between the ages of 18 and 64 years is ongoing at a single site in Australia.

We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection. We measured antibody titers using hemagglutination-inhibition and microneutralization assays at baseline and 21 days after vaccination. The coprimary immunogenicity end points were the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay, the proportion of subjects with either seroconversion or a significant increase in antibody titer, and the factor increase in the geometric mean titer.

By day 21 after the first dose, antibody titers of 1:40 or more were observed in 114 of 120 subjects (95.0%) who received the 15-g dose and in 106 of 119 subjects (89.1%) who received the 30-g dose. A similar result was observed after the second dose of vaccine. No deaths, serious adverse events, or adverse events of special interest were reported. Local discomfort (e.g., injection-site tenderness or pain) was reported by 56.3% of subjects, and systemic symptoms (e.g., headache) by 53.8% of subjects after each dose. Nearly all events were mild to moderate in intensity.

A single 15-g dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.
",Control Control Control Control Control Control Control Control Control c copy Control v paste,"['2023-06-01T15:23:03.233Z', '2023-06-01T15:23:03.703Z', '2023-06-01T15:23:03.731Z', '2023-06-01T15:23:03.753Z', '2023-06-01T15:23:03.783Z', '2023-06-01T15:23:03.799Z', '2023-06-01T15:23:03.862Z', '2023-06-01T15:23:03.877Z', '2023-06-01T15:23:03.881Z', '2023-06-01T15:23:03.902Z', None, '2023-06-01T15:23:08.814Z', '2023-06-01T15:23:09.162Z', None]","We evaluated the immunogenicity and safety of the vaccine after each of two scheduled doses, administered 21 days apart. A total of 240 subjects, equally divided into two age groups ((50 years and  50 years), were enrolled and underwent randomization to receive either 15 g or 30 g of hemagglutinin antigen by intramuscular injection.",True,real
3MD8CKRQZZ8X98V71EEJ06BQ5DPRJI,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",copy Control v paste,"[None, '2023-06-01T06:54:45.116Z', '2023-06-01T06:54:45.599Z', None]","The inverse association between coffee consumption and mortality was consistent regardless of cumulative caffeine intake up to 2.5 g/d. Further associated factors such as reported diet, BMI, physical activity, smoking, were controlled for in the analysis. The National Institutes of Health-AARP Diet and Health Study collected detailed dietary and other lifestyle information from over 500,000 participants. This study adds to the evidence that coffee consumption might have beneficial health effects.",True,synthetic
3MD8CKRQZZ8X98V71EEJ06BQ5DPRJI,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",CapsLock Control c copy Control v paste Shift W Control c copy Control v paste . Control c copy Control v paste .,"['2023-06-01T07:11:12.333Z', '2023-06-01T07:11:12.335Z', '2023-06-01T07:11:12.429Z', None, '2023-06-01T07:11:13.565Z', '2023-06-01T07:11:13.764Z', None, '2023-06-01T07:11:16.909Z', '2023-06-01T07:11:17.124Z', '2023-06-01T07:11:20.212Z', '2023-06-01T07:11:34.484Z', '2023-06-01T07:11:34.723Z', None, '2023-06-01T07:11:36.917Z', '2023-06-01T07:11:37.267Z', None, '2023-06-01T07:11:39.213Z', '2023-06-01T07:11:39.867Z', '2023-06-01T07:11:55.884Z', '2023-06-01T07:11:56.220Z', None, '2023-06-01T07:11:57.492Z', '2023-06-01T07:11:57.666Z', None, '2023-06-01T07:11:59.619Z']","Women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee. In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data.",True,real
3MD8CKRQZZ8X98V71EEJ06BQ5DPRJI,"Association of Coffee Drinking with Total and Cause-Specific Mortality

Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear.

We examined the association of coffee drinking with subsequent total and cause-specific mortality among 229,119 men and 173,141 women in the National Institutes of Health - AARP Diet and Health Study who were 50 to 71 years of age at baseline. Participants with cancer, heart disease, and stroke were excluded. Coffee consumption was assessed once at baseline.

During 5,148,760 person-years of follow-up between 1995 and 2008, a total of 33,731 men and 18,784 women died. In age-adjusted models, the risk of death was increased among coffee drinkers. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Adjusted hazard ratios for death among men who drank coffee as compared with those who did not were as follows; 0.99 (95% confidence interval (CI), 0.95 to 1.04) for drinking less than 1 cup per day, 0.94 (95% CI, 0.90 to 0.99) for 1 cup, 0.90 (95% CI, 0.86 to 0.93) for 2 or 3 cups, 0.88 (95% CI, 0.84 to 0.93) for 4 or 5 cups, and 0.90 (95% CI, 0.85 to 0.96) for 6 or more cups of coffee per day (P (0.001 for trend); the respective hazard ratios among women were 1.01 (95% CI, 0.96 to 1.07), 0.95 (95% CI, 0.90 to 1.01), 0.87 (95% CI, 0.83 to 0.92), 0.84 (95% CI, 0.79 to 0.90), and 0.85 (95% CI, 0.78 to 0.93) (P (0.001 for trend). Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline.

In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data. (Funded by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics.)
",copy paste paste Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace paste Backspace Backspace Backspace Backspace copy paste copy paste copy paste,"[None, None, None, '2023-06-01T07:33:56.876Z', '2023-06-01T07:33:57.350Z', '2023-06-01T07:33:57.377Z', '2023-06-01T07:33:57.407Z', '2023-06-01T07:33:57.437Z', '2023-06-01T07:33:57.477Z', '2023-06-01T07:33:57.507Z', '2023-06-01T07:33:57.537Z', '2023-06-01T07:33:57.580Z', '2023-06-01T07:33:57.607Z', '2023-06-01T07:33:57.644Z', '2023-06-01T07:34:02.569Z', None, '2023-06-01T07:34:14.137Z', '2023-06-01T07:34:14.312Z', '2023-06-01T07:34:14.465Z', '2023-06-01T07:34:14.615Z', None, None, '2023-06-01T07:34:41.635Z', None, None, '2023-06-01T07:35:25.891Z', None, None]","Coffee is one of the most widely consumed beverages, but the association between coffee consumption and the risk of death remains unclear. However, coffee drinkers were also more likely to smoke, and, after adjustment for tobacco-smoking status and other potential confounders, there was a significant inverse association between coffee consumption and mortality. Inverse associations were observed for deaths due to heart disease, respiratory disease, stroke, injuries and accidents, diabetes, and infections, but not for deaths due to cancer. Results were similar in subgroups, including persons who had never smoked and persons who reported very good to excellent health at baseline. In this large prospective study, coffee consumption was inversely associated with total and cause-specific mortality. Whether this was a causal or associational finding can not be determined from our data.",True,real
37AQKJ12TX943Q44HXXI2RZHR0DTT2,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
",Control v paste,"['2023-06-01T07:32:49.218Z', '2023-06-01T07:32:49.418Z', None]","We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.",True,real
37AQKJ12TX943Q44HXXI2RZHR0DTT2,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
",copy copy paste,"[None, None, None]","Our analysis suggests that the use of rosiglitazone to treat type 2 diabetes mellitus is associated with an increased risk of myocardial infarction and death from cardiovascular causes. This analysis included 42 randomized studies with over 40,000 total subjects aged 56 on average, and with an average baseline glycated hemoglobin level of 8.2%. The odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03) and for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06). Despite the limitations of relying on the available literature, these results indicate a potential for serious adverse cardiovascular effects and should be considered before rosiglitazone is prescribed.",True,real
37AQKJ12TX943Q44HXXI2RZHR0DTT2,"Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval (CI), 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.
",Control c copy Control v paste,"['2023-06-01T15:58:57.034Z', '2023-06-01T15:58:57.319Z', None, '2023-06-01T15:59:27.619Z', '2023-06-01T15:59:27.953Z', None]","Rosiglitazone, a widely used treatment for type 2 diabetes, has been found to be associated with an increased risk of myocardial infarction and cardiovascular death in an analysis of data from 42 randomized control trials. The odds ratio for myocardial infarction was 1.43 (95% CI, 1.03 to 1.98) and for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74). Time-to-event analysis could not be completed due to a lack of access to original source data. These findings suggest potential serious adverse cardiovascular effects from rosiglitazone and should be taken into account when prescribing it for treatment of type 2 diabetes.",True,synthetic
3ZQA3IO31BCNHENNJXR92BAZ0961OG,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
",Backspace Backspace Backspace Backspace Backspace Backspace Control Control Control Control Control Control Control C copy C copy C copy Control Control Control Control Control Control Control Control Control Control Control V paste Backspace,"['2023-06-01T06:50:16.057Z', '2023-06-01T06:50:16.246Z', '2023-06-01T06:50:16.423Z', '2023-06-01T06:50:16.599Z', '2023-06-01T06:50:16.790Z', '2023-06-01T06:50:17.058Z', '2023-06-01T06:56:34.011Z', '2023-06-01T06:56:34.510Z', '2023-06-01T06:56:34.547Z', '2023-06-01T06:56:34.576Z', '2023-06-01T06:56:34.608Z', '2023-06-01T06:56:34.644Z', '2023-06-01T06:56:34.676Z', '2023-06-01T06:56:34.699Z', None, '2023-06-01T06:56:35.346Z', None, '2023-06-01T06:56:35.350Z', None, '2023-06-01T06:56:36.795Z', '2023-06-01T06:56:37.297Z', '2023-06-01T06:56:37.325Z', '2023-06-01T06:56:37.362Z', '2023-06-01T06:56:37.392Z', '2023-06-01T06:56:37.425Z', '2023-06-01T06:56:37.458Z', '2023-06-01T06:56:37.491Z', '2023-06-01T06:56:37.524Z', '2023-06-01T06:56:37.562Z', '2023-06-01T06:56:37.597Z', '2023-06-01T06:56:37.597Z', None, '2023-06-01T06:56:39.438Z']","68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women",True,real
3ZQA3IO31BCNHENNJXR92BAZ0961OG,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
",copy paste copy . paste copy paste,"[None, None, None, '2023-06-01T11:10:43.396Z', '2023-06-01T11:10:43.691Z', None, None, None]","r a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients). In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.",True,real
3ZQA3IO31BCNHENNJXR92BAZ0961OG,"Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor - positive breast cancer.

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor - positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials.

After a median follow-up of 68 months, disease-free survival at 5 years was 91.1% in the exemestane - ovarian suppression group and 87.3% in the tamoxifen - ovarian suppression group (hazard ratio for disease recurrence, second invasive cancer, or death, 0.72; 95% confidence interval (CI), 0.60 to 0.85; P (0.001). The rate of freedom from breast cancer at 5 years was 92.8% in the exemestane - ovarian suppression group, as compared with 88.8% in the tamoxifen - ovarian suppression group (hazard ratio for recurrence, 0.66; 95% CI, 0.55 to 0.80; P (0.001). With 194 deaths (4.1% of the patients), overall survival did not differ significantly between the two groups (hazard ratio for death in the exemestane - ovarian suppression group, 1.14; 95% CI, 0.86 to 1.51; P = 0.37). Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the exemestane - ovarian suppression group and 29.4% of those in the tamoxifen - ovarian suppression group, with profiles similar to those for postmenopausal women.

In premenopausal women with hormone-receptor - positive early breast cancer, adjuvant treatment with exemestane plus ovarian suppression, as compared with tamoxifen plus ovarian suppression, significantly reduced recurrence.
",copy paste,"[None, None]","In this study, premenopausal women with hormone-receptor positive early breast cancer were randomly assigned to an adjuvant treatment of either exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for five years. After a median follow-up 68 months, the disease-free survival rate at 5 years was 91.1% in the exemestane-ovarian suppression group, compared to 87.3% in the tamoxifen-ovarian suppression group. The rate of freedom from breast cancer at five years was 92.8% in the exemestane-ovarian suppression group compared to 88.8% in the tamoxifen-ovarian suppression group. Adverse events were mild and comparable between the two groups. In conclusion, these results indicate that exemestane plus ovarian suppression treatments significantly reduce recurrence rates of breast cancer among premenopausal patients, compared to tamoxifen and ovarian suppression treatments.",True,synthetic
32CXT5U14GO05JR5E4CXGRPWW108UK,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
","Control c copy Control v paste Control c copy Control v paste , Shift T h e d a t a c o l l e c t e d 6 6 c o u n t r i e s a n d n e w m e t a a n s a Backspace Backspace a ; u s o s p f 1 0 7 Control c copy Control v paste Control c copy Control v paste Backspace Backspace Backspace Backspace Backspace o f Control c copy Control v paste Control c copy Backspace Control v paste Control c copy . Control v paste","['2023-06-01T07:26:33.358Z', '2023-06-01T07:26:33.723Z', None, '2023-06-01T07:26:39.021Z', '2023-06-01T07:26:39.428Z', None, '2023-06-01T07:26:48.379Z', '2023-06-01T07:27:02.955Z', '2023-06-01T07:27:03.419Z', None, '2023-06-01T07:27:07.511Z', '2023-06-01T07:27:07.837Z', None, '2023-06-01T07:27:10.426Z', '2023-06-01T07:27:11.652Z', '2023-06-01T07:27:21.102Z', '2023-06-01T07:27:21.789Z', '2023-06-01T07:27:21.995Z', '2023-06-01T07:27:22.113Z', '2023-06-01T07:27:22.226Z', '2023-06-01T07:27:23.241Z', '2023-06-01T07:27:24.253Z', '2023-06-01T07:27:24.426Z', '2023-06-01T07:27:24.603Z', '2023-06-01T07:27:24.771Z', '2023-06-01T07:27:25.013Z', '2023-06-01T07:27:25.126Z', '2023-06-01T07:27:25.350Z', '2023-06-01T07:27:25.507Z', '2023-06-01T07:27:25.653Z', '2023-06-01T07:27:25.867Z', '2023-06-01T07:27:26.152Z', '2023-06-01T07:27:26.267Z', '2023-06-01T07:27:26.496Z', '2023-06-01T07:27:26.786Z', '2023-06-01T07:27:29.574Z', '2023-06-01T07:27:29.723Z', '2023-06-01T07:27:29.844Z', '2023-06-01T07:27:30.450Z', '2023-06-01T07:27:30.549Z', '2023-06-01T07:27:30.710Z', '2023-06-01T07:27:30.929Z', '2023-06-01T07:27:31.118Z', '2023-06-01T07:27:31.358Z', '2023-06-01T07:27:31.532Z', '2023-06-01T07:27:31.656Z', '2023-06-01T07:27:31.890Z', '2023-06-01T07:27:32.189Z', '2023-06-01T07:27:42.492Z', '2023-06-01T07:27:42.632Z', '2023-06-01T07:27:42.730Z', '2023-06-01T07:27:42.878Z', '2023-06-01T07:27:43.693Z', '2023-06-01T07:27:43.810Z', '2023-06-01T07:27:43.904Z', '2023-06-01T07:27:44.240Z', '2023-06-01T07:27:45.005Z', '2023-06-01T07:27:45.151Z', '2023-06-01T07:27:45.383Z', '2023-06-01T07:27:46.276Z', '2023-06-01T07:27:46.592Z', '2023-06-01T07:27:47.946Z', '2023-06-01T07:27:48.105Z', '2023-06-01T07:27:48.417Z', '2023-06-01T07:27:48.770Z', '2023-06-01T07:27:50.115Z', '2023-06-01T07:27:50.399Z', '2023-06-01T07:27:51.208Z', '2023-06-01T07:27:51.556Z', '2023-06-01T07:27:51.767Z', '2023-06-01T07:27:51.967Z', '2023-06-01T07:27:52.179Z', '2023-06-01T07:27:52.298Z', '2023-06-01T07:27:52.501Z', '2023-06-01T07:27:53.393Z', '2023-06-01T07:27:53.520Z', '2023-06-01T07:27:53.610Z', '2023-06-01T07:27:54.207Z', '2023-06-01T07:27:54.389Z', '2023-06-01T07:27:54.616Z', '2023-06-01T07:27:54.826Z', '2023-06-01T07:28:01.511Z', '2023-06-01T07:28:01.774Z', None, '2023-06-01T07:28:04.126Z', '2023-06-01T07:28:04.497Z', None, '2023-06-01T07:28:10.458Z', '2023-06-01T07:28:10.911Z', None, '2023-06-01T07:28:14.903Z', '2023-06-01T07:28:15.102Z', None, '2023-06-01T07:28:20.025Z', '2023-06-01T07:28:20.244Z', '2023-06-01T07:28:20.450Z', '2023-06-01T07:28:20.986Z', '2023-06-01T07:28:21.370Z', '2023-06-01T07:28:23.587Z', '2023-06-01T07:28:24.216Z', '2023-06-01T07:28:34.579Z', '2023-06-01T07:28:34.997Z', None, '2023-06-01T07:28:38.049Z', '2023-06-01T07:28:38.260Z', None, '2023-06-01T07:28:55.754Z', '2023-06-01T07:28:55.947Z', None, '2023-06-01T07:29:01.086Z', '2023-06-01T07:29:01.283Z', '2023-06-01T07:29:01.590Z', None, '2023-06-01T07:29:23.735Z', '2023-06-01T07:29:24.010Z', None, '2023-06-01T07:29:26.666Z', '2023-06-01T07:29:26.854Z', '2023-06-01T07:29:27.093Z', '2023-06-01T07:29:27.296Z', None]","Global Sodium Consumption and Death from Cardiovascular Causes blood pressure, a risk factor for cardiovascular disease, The data collected 66 countries and new meta-analysis of 107 randomized interventions,he effects of blood pressure on cardiovascular mortality, Cause-specific mortality was derived from the Global Burden of Disease. In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women.",True,real
32CXT5U14GO05JR5E4CXGRPWW108UK,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
",copy paste copy paste copy paste T H E Backspace Backspace Backspace CapsLock h e p e r s o n a Backspace Backspace d Backspace s a r e t a k i n g m o r e b a d f o r m h e r h e a l t h . n o w a d a y Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace n o w a d a y s t h e p e o p l e s m a k e Backspace Backspace i n g h e r h e a l t h l o w l y . t h e p e r s o n s a r e t r y i n g t o t a k e c a r e o f h e r l i f e a n d h e a l t h t h a t s t h e Backspace m o s t i m p o r t a n t o f b a s i c p e r s o n Backspace s l i f e . Backspace copy paste,"[None, None, None, None, '2023-06-01T06:58:39.342Z', None, None, '2023-06-01T06:58:55.857Z', '2023-06-01T06:58:56.113Z', '2023-06-01T06:58:56.241Z', '2023-06-01T06:58:56.462Z', '2023-06-01T06:58:57.654Z', '2023-06-01T06:58:57.879Z', '2023-06-01T06:58:58.094Z', '2023-06-01T06:59:00.601Z', '2023-06-01T06:59:01.070Z', '2023-06-01T06:59:01.362Z', '2023-06-01T06:59:01.536Z', '2023-06-01T06:59:01.943Z', '2023-06-01T06:59:02.129Z', '2023-06-01T06:59:02.416Z', '2023-06-01T06:59:02.832Z', '2023-06-01T06:59:03.070Z', '2023-06-01T06:59:03.400Z', '2023-06-01T06:59:03.742Z', '2023-06-01T06:59:04.001Z', '2023-06-01T06:59:04.846Z', '2023-06-01T06:59:07.161Z', '2023-06-01T06:59:07.514Z', '2023-06-01T06:59:08.705Z', '2023-06-01T06:59:09.033Z', '2023-06-01T06:59:11.857Z', '2023-06-01T06:59:14.170Z', '2023-06-01T06:59:14.584Z', '2023-06-01T06:59:14.810Z', '2023-06-01T06:59:15.001Z', '2023-06-01T06:59:15.250Z', '2023-06-01T06:59:16.192Z', '2023-06-01T06:59:16.528Z', '2023-06-01T06:59:16.857Z', '2023-06-01T06:59:17.083Z', '2023-06-01T06:59:17.320Z', '2023-06-01T06:59:17.538Z', '2023-06-01T06:59:17.787Z', '2023-06-01T06:59:18.264Z', '2023-06-01T06:59:18.704Z', '2023-06-01T06:59:19.131Z', '2023-06-01T06:59:19.307Z', '2023-06-01T06:59:19.545Z', '2023-06-01T06:59:20.433Z', '2023-06-01T06:59:20.682Z', '2023-06-01T06:59:21.018Z', '2023-06-01T06:59:21.200Z', '2023-06-01T06:59:21.473Z', '2023-06-01T06:59:21.842Z', '2023-06-01T06:59:21.986Z', '2023-06-01T06:59:22.234Z', '2023-06-01T06:59:22.442Z', '2023-06-01T06:59:23.113Z', '2023-06-01T06:59:23.337Z', '2023-06-01T06:59:23.569Z', '2023-06-01T06:59:23.770Z', '2023-06-01T06:59:24.186Z', '2023-06-01T06:59:24.473Z', '2023-06-01T06:59:25.154Z', '2023-06-01T06:59:25.362Z', '2023-06-01T06:59:25.786Z', '2023-06-01T06:59:26.017Z', '2023-06-01T06:59:26.547Z', '2023-06-01T06:59:26.809Z', '2023-06-01T06:59:27.713Z', '2023-06-01T06:59:28.121Z', '2023-06-01T06:59:28.657Z', '2023-06-01T06:59:29.946Z', '2023-06-01T06:59:30.353Z', '2023-06-01T06:59:30.720Z', '2023-06-01T06:59:30.952Z', '2023-06-01T06:59:31.304Z', '2023-06-01T06:59:32.657Z', '2023-06-01T06:59:32.881Z', '2023-06-01T06:59:33.137Z', '2023-06-01T06:59:33.389Z', '2023-06-01T06:59:34.017Z', '2023-06-01T06:59:36.435Z', '2023-06-01T06:59:57.522Z', '2023-06-01T06:59:58.345Z', '2023-06-01T07:00:28.464Z', '2023-06-01T07:00:28.785Z', '2023-06-01T07:00:29.224Z', '2023-06-01T07:00:34.856Z', '2023-06-01T07:00:35.280Z', '2023-06-01T07:00:35.819Z', '2023-06-01T07:00:36.316Z', '2023-06-01T07:00:36.333Z', '2023-06-01T07:00:36.528Z', '2023-06-01T07:00:37.151Z', '2023-06-01T07:00:37.392Z', '2023-06-01T07:00:37.696Z', '2023-06-01T07:00:37.756Z', '2023-06-01T07:00:38.129Z', '2023-06-01T07:00:38.750Z', '2023-06-01T07:00:40.007Z', '2023-06-01T07:00:40.215Z', '2023-06-01T07:00:40.553Z', '2023-06-01T07:00:40.918Z', '2023-06-01T07:00:41.210Z', '2023-06-01T07:00:41.294Z', '2023-06-01T07:00:41.672Z', '2023-06-01T07:00:41.854Z', '2023-06-01T07:00:42.090Z', '2023-06-01T07:00:42.299Z', '2023-06-01T07:00:42.480Z', '2023-06-01T07:00:43.692Z', '2023-06-01T07:00:45.305Z', '2023-06-01T07:00:45.879Z', '2023-06-01T07:00:46.191Z', '2023-06-01T07:00:46.434Z', '2023-06-01T07:00:46.672Z', '2023-06-01T07:00:47.312Z', '2023-06-01T07:00:47.601Z', '2023-06-01T07:00:47.823Z', '2023-06-01T07:00:47.986Z', '2023-06-01T07:00:49.071Z', '2023-06-01T07:00:49.451Z', '2023-06-01T07:00:49.759Z', '2023-06-01T07:00:49.944Z', '2023-06-01T07:00:50.376Z', '2023-06-01T07:00:50.641Z', '2023-06-01T07:00:50.954Z', '2023-06-01T07:00:51.507Z', '2023-06-01T07:00:51.585Z', '2023-06-01T07:00:51.961Z', '2023-06-01T07:00:52.368Z', '2023-06-01T07:00:52.718Z', '2023-06-01T07:00:53.763Z', '2023-06-01T07:00:53.768Z', '2023-06-01T07:00:54.145Z', '2023-06-01T07:00:54.399Z', '2023-06-01T07:00:54.687Z', '2023-06-01T07:00:54.897Z', '2023-06-01T07:00:55.399Z', '2023-06-01T07:00:55.807Z', '2023-06-01T07:00:55.976Z', '2023-06-01T07:00:56.360Z', '2023-06-01T07:00:56.585Z', '2023-06-01T07:00:56.962Z', '2023-06-01T07:00:57.104Z', '2023-06-01T07:00:57.447Z', '2023-06-01T07:00:58.024Z', '2023-06-01T07:00:58.273Z', '2023-06-01T07:00:58.569Z', '2023-06-01T07:00:58.705Z', '2023-06-01T07:01:39.407Z', '2023-06-01T07:01:48.376Z', '2023-06-01T07:01:48.626Z', '2023-06-01T07:01:49.183Z', '2023-06-01T07:01:49.640Z', '2023-06-01T07:01:49.922Z', '2023-06-01T07:01:50.214Z', '2023-06-01T07:01:50.425Z', '2023-06-01T07:01:50.746Z', '2023-06-01T07:01:50.975Z', '2023-06-01T07:01:51.283Z', '2023-06-01T07:01:51.657Z', '2023-06-01T07:01:51.937Z', '2023-06-01T07:01:52.308Z', '2023-06-01T07:01:52.556Z', '2023-06-01T07:01:53.154Z', '2023-06-01T07:01:53.681Z', '2023-06-01T07:01:54.087Z', '2023-06-01T07:01:54.201Z', '2023-06-01T07:01:54.415Z', '2023-06-01T07:01:54.633Z', '2023-06-01T07:01:56.193Z', '2023-06-01T07:01:56.498Z', '2023-06-01T07:01:56.906Z', '2023-06-01T07:02:36.155Z', '2023-06-01T07:02:36.353Z', '2023-06-01T07:02:36.603Z', '2023-06-01T07:02:36.793Z', '2023-06-01T07:02:37.196Z', '2023-06-01T07:02:37.480Z', '2023-06-01T07:02:37.958Z', '2023-06-01T07:02:38.390Z', '2023-06-01T07:02:38.675Z', '2023-06-01T07:02:39.004Z', '2023-06-01T07:02:39.272Z', '2023-06-01T07:02:39.620Z', '2023-06-01T07:02:39.750Z', '2023-06-01T07:02:41.226Z', '2023-06-01T07:02:41.465Z', '2023-06-01T07:02:41.837Z', '2023-06-01T07:02:42.056Z', '2023-06-01T07:02:42.490Z', '2023-06-01T07:02:43.113Z', '2023-06-01T07:02:43.416Z', '2023-06-01T07:02:44.327Z', '2023-06-01T07:02:44.527Z', '2023-06-01T07:02:44.779Z', '2023-06-01T07:02:45.175Z', '2023-06-01T07:02:45.514Z', '2023-06-01T07:02:45.526Z', '2023-06-01T07:02:45.974Z', '2023-06-01T07:02:46.710Z', '2023-06-01T07:02:46.832Z', '2023-06-01T07:02:47.181Z', '2023-06-01T07:02:51.739Z', '2023-06-01T07:02:53.265Z', '2023-06-01T07:02:55.665Z', '2023-06-01T07:02:55.896Z', '2023-06-01T07:02:56.145Z', '2023-06-01T07:02:56.407Z', '2023-06-01T07:02:56.757Z', '2023-06-01T07:02:57.360Z', '2023-06-01T07:02:57.608Z', '2023-06-01T07:02:57.871Z', '2023-06-01T07:02:58.071Z', '2023-06-01T07:02:58.469Z', '2023-06-01T07:02:59.233Z', '2023-06-01T07:02:59.417Z', '2023-06-01T07:02:59.712Z', '2023-06-01T07:03:00.825Z', '2023-06-01T07:03:01.033Z', '2023-06-01T07:03:01.822Z', '2023-06-01T07:03:02.047Z', '2023-06-01T07:03:02.302Z', '2023-06-01T07:03:02.680Z', '2023-06-01T07:03:03.175Z', '2023-06-01T07:03:03.464Z', '2023-06-01T07:03:03.737Z', '2023-06-01T07:03:04.097Z', '2023-06-01T07:03:04.480Z', '2023-06-01T07:03:05.152Z', '2023-06-01T07:03:05.415Z', '2023-06-01T07:03:05.665Z', '2023-06-01T07:03:06.065Z', '2023-06-01T07:03:06.584Z', '2023-06-01T07:03:06.921Z', '2023-06-01T07:03:07.383Z', '2023-06-01T07:03:08.823Z', '2023-06-01T07:03:09.741Z', '2023-06-01T07:03:10.038Z', '2023-06-01T07:03:10.410Z', '2023-06-01T07:03:10.728Z', '2023-06-01T07:03:11.119Z', '2023-06-01T07:03:11.423Z', '2023-06-01T07:03:11.872Z', '2023-06-01T07:03:17.679Z', None, None, '2023-06-01T07:03:47.240Z']","In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day. High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain. In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya. The persons are taking more bad form her health. nowadays the peoples making her health lowly. the persons are trying to take care of her life and health that the most important of basic persons life. We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.",True,real
32CXT5U14GO05JR5E4CXGRPWW108UK,"Global Sodium Consumption and Death from Cardiovascular Causes

High sodium intake increases blood pressure, a risk factor for cardiovascular disease, but the effects of sodium intake on global cardiovascular mortality are uncertain.

We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country.

In 2010, the estimated mean level of global sodium consumption was 3.95 g per day, and regional mean levels ranged from 2.18 to 5.51 g per day. Globally, 1.65 million annual deaths from cardiovascular causes (95% uncertainty interval (confidence interval), 1.10 million to 2.22 million) were attributed to sodium intake above the reference level; 61.9% of these deaths occurred in men and 38.1% occurred in women. These deaths accounted for nearly 1 of every 10 deaths from cardiovascular causes (9.5%). Four of every 5 deaths (84.3%) occurred in low - and middle-income countries, and 2 of every 5 deaths (40.4%) were premature (before 70 years of age). The rate of death from cardiovascular causes associated with sodium intake above the reference level was highest in the country of Georgia and lowest in Kenya.

In this modeling study, 1.65 million deaths from cardiovascular causes that occurred in 2010 were attributed to sodium consumption above a reference level of 2.0 g per day.
",copy paste T H E C O U N T R Y M A Y T O H A N D L I N G T H E CapsLock Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace Backspace copy paste,"[None, None, '2023-06-01T11:06:46.590Z', '2023-06-01T11:06:46.970Z', '2023-06-01T11:06:47.186Z', '2023-06-01T11:06:47.412Z', '2023-06-01T11:06:47.594Z', '2023-06-01T11:06:48.035Z', '2023-06-01T11:06:48.324Z', '2023-06-01T11:06:48.634Z', '2023-06-01T11:06:48.859Z', '2023-06-01T11:06:49.243Z', '2023-06-01T11:06:49.474Z', '2023-06-01T11:06:49.637Z', '2023-06-01T11:06:49.956Z', '2023-06-01T11:06:50.412Z', '2023-06-01T11:06:50.650Z', '2023-06-01T11:06:50.924Z', '2023-06-01T11:06:51.241Z', '2023-06-01T11:06:52.100Z', '2023-06-01T11:06:52.369Z', '2023-06-01T11:06:52.698Z', '2023-06-01T11:06:53.075Z', '2023-06-01T11:06:53.535Z', '2023-06-01T11:06:53.826Z', '2023-06-01T11:06:54.107Z', '2023-06-01T11:06:54.651Z', '2023-06-01T11:06:54.899Z', '2023-06-01T11:06:55.187Z', '2023-06-01T11:06:55.610Z', '2023-06-01T11:06:55.882Z', '2023-06-01T11:06:56.227Z', '2023-06-01T11:06:56.458Z', '2023-06-01T11:06:56.629Z', '2023-06-01T11:06:56.866Z', '2023-06-01T11:06:59.219Z', '2023-06-01T11:07:16.275Z', '2023-06-01T11:07:16.774Z', '2023-06-01T11:07:16.809Z', '2023-06-01T11:07:16.841Z', '2023-06-01T11:07:16.872Z', '2023-06-01T11:07:16.906Z', '2023-06-01T11:07:16.941Z', '2023-06-01T11:07:16.973Z', '2023-06-01T11:07:17.006Z', '2023-06-01T11:07:17.037Z', '2023-06-01T11:07:17.072Z', '2023-06-01T11:07:17.104Z', '2023-06-01T11:07:17.137Z', '2023-06-01T11:07:17.172Z', '2023-06-01T11:07:17.204Z', '2023-06-01T11:07:17.236Z', '2023-06-01T11:07:17.271Z', '2023-06-01T11:07:17.303Z', '2023-06-01T11:07:17.335Z', '2023-06-01T11:07:17.370Z', '2023-06-01T11:07:17.402Z', '2023-06-01T11:07:17.434Z', '2023-06-01T11:07:17.469Z', '2023-06-01T11:07:18.107Z', '2023-06-01T11:07:18.347Z', '2023-06-01T11:07:18.596Z', '2023-06-01T11:07:18.833Z', '2023-06-01T11:07:19.035Z', '2023-06-01T11:07:19.266Z', '2023-06-01T11:07:19.491Z', '2023-06-01T11:07:19.737Z', '2023-06-01T11:07:19.962Z', None, None]","We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country. The effects of sodium on blood pressure, according to age, race, and the presence or absence of hypertension, were calculated from data in a new meta-analysis of 107 randomized interventions, and the effects of blood pressure on cardiovascular mortality, according to age, were calculated from a meta-analysis of cohorts. Cause-specific mortality was derived from the Global Burden of Disease Study 2010. Using comparative risk assessment, we estimated the cardiovascular effects of current sodium intake, as compared with a reference intake of 2.0 g of sodium per day, according to age, sex, and country. We collected data from surveys on sodium intake as determined by urinary excretion and diet in persons from 66 countries (accounting for 74.1% of adults throughout the world), and we used these data to quantify the global consumption of sodium according to age, sex, and country.",True,real
